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Impaired ribosome function is the underlying etiology in a group of bone marrow failure 
syndromes called ribosomopathies. However, how ribosomes are regulated remains poorly 
understood, as are approaches to restore hematopoietic stem cell (HSC) function attributable to 
defective ribosome biogenesis. Here we reveal a role for the E3 ubiquitin ligase HectD1 in 
regulating HSC function via ribosome assembly and protein translation. Hectd1-deficient HSCs 
exhibit a striking defect in transplantation ability and ex vivo maintenance, concomitant with a 
reduced protein synthesis and growth rate under stress conditions. Mechanistically, HectD1 
ubiquitinates and degrades ZNF622, an assembly factor for the ribosomal 60S subunit. HectD1 
loss led to an accumulation of ZNF622 and the anti-association factor eIF6 on the 60S, resulting 
in 60S/40S joining defects. Importantly, Znf622 depletion in Hectd1-deficient HSCs restored 
ribosomal subunit joining, protein synthesis, and HSC reconstitution capacity. These findings 







At the steady-state, protein synthesis rate is low in adult hematopoietic stem cells (HSCs) as 
compared with committed progenitors or differentiated cells (Signer et al., 2014). Tightly-
regulated protein synthesis rate is critical for HSC maintenance and function (Signer et al., 2014; 
Signer et al., 2016). HSC expansion under regenerative or stress conditions demands increased 
ribosome biogenesis and protein synthesis. Appropriate ribosome biogenesis and assembly ensures 
the translation efficiency and fidelity of proteins, which are important for normal development as 
well as prevention of cancer. Mutations in ribosomal proteins and gene products affecting 
ribosome biogenesis and protein synthesis are associated with human diseases marked by 
hematopoietic dysfunction (Sulima et al., 2017). However, how ribosome assembly is regulated in 
HSCs remains poorly understood, as is its contribution to hematopoietic diseases.  
    
The biogenesis of the two ribosomal subunits 40S and 60S occurs largely in the nucleus; upon 
nuclear export, they separately undergo final stages of maturation in the cytoplasm that are 
regulated by distinct assembly factors and incorporation of the last few cytoplasmic ribosome 
proteins (de la Cruz et al., 2015). These assembly factors proofread and protect key functional sites 
on the ribosome and prevent premature joining of 60S and 40S subunits, to ensure regulated 
formation of functional 80S monosomes and appropriate translation (Klinge and Woolford, 2019).  
“Ribosomopathies” are characterized by a group of inherited bone marrow failure (BMF) 
syndromes with impaired ribosome function. Individuals with “ribosomopathies” are deficient in 
HSCs or specific lineages of blood formation, and yet are predisposed to elevated leukemia and 
cancer risks (Ruggero and Shimamura, 2014). One such example is Shwachman-Diamond 
syndrome (SDS), that is etiologically linked to ribosome dysfunction arising from mutations of 
ribosome assembly factors (Warren, 2018; Woloszynek et al., 2004). Germline mutations in three 
different genes (SBDS, DNAJC21, and EFL1) involved in the 60S maturation and assembly all 
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cause SDS (Boocock et al., 2003; Dhanraj et al., 2017; Tan et al., 2019; Tummala et al., 2016; 
Woloszynek et al., 2004), implying that HSCs are especially sensitive to perturbations in ribosome 
assembly. These mutations result in ribosomal subunit joining defects and decreased protein 
synthesis rate (Finch et al., 2011; Menne et al., 2007; Tan et al., 2019; Wong et al., 2011). The 
question of how ribosomal abnormalities cause marrow failure and cancer predisposition is 
therefore of fundamental biological and clinical interest. However, how assembly factors 
themselves are regulated and their impact on hematopoietic regeneration remain poorly understood.  
 
HectD1, a member of HECT domain E3 ligases, plays an indispensable role in early 
embryogenesis. The HECT domain of HectD1 catalyzes the ubiquitination of its substrates to 
modulate protein stability, protein-protein interaction, and cellular localization. HectD1 has been 
reported to regulate various biological processes, including signaling transduction, gene 
transcription, development, and lipid homeostasis (Aleidi et al., 2018; Li et al., 2015; Sarkar and 
Zohn, 2012; Sugrue et al., 2019; Tran et al., 2013). Here, we identify HectD1 as a critical 
determinant of HSC function via its direct ubiquitination of ribosomal assembly factor. This 
discovery provides an important new facet to our understanding of ubiquitin-coordinated 
ribosomal assembly in stem cell biology. 
 
Results 
Generation of a conditional Hectd1 knockout mice in hematopoietic cells.  
Hectd1 germline knockout (KO) leads to mouse embryonic lethality due to defects in neural tube 
closure and impaired placenta development (D'Alonzo et al., 2019; Sarkar et al., 2014; Zohn et al., 
2007). To explore a potential role for HectD1 in hematopoiesis, we studied a conditional Hectd1 
knockout (cKO) mouse model (Figure S1A). The floxed alleles of Hectd1 that target exon 3 
(Hectd1f/f) were crossed with Vav-cre transgenic mice, in which the Cre recombinase is under the 
 
 5 
control of the Vav promoter to allow pan-hematopoietic excision of Hectd1 in all hematopoietic 
cells (Hectd1f/f;Vav). Deletion of exon 3 is predicted to generate an early stop codon in exon 4, thus 
producing a non-functional 50 amino acid truncated protein. To evaluate deletion efficiency, we 
plated bone marrow (BM) cells from Hectd1f/f and Hectd1f/f;Vav mice into semisolid methylcellulose 
culture and confirmed a nearly 100% deletion efficiency by genotyping individual colonies (Figure 
S1B). Quantitative PCR analysis (qRT-PCR) demonstrated the specific targeting of exon 3 of the 
Hectd1 gene (Figures S1C and S1D). Moreover, HectD1 protein was undetectable in Hectd1f/f;Vav  
BM cells (Figure S1E). Together, these data suggest that Hectd1 was efficiently and specifically 
deleted in all hematopoietic cells in our cKO mouse model. 
 
Hectd1 deficiency impairs HSC repopulation capacity and decreases functional HSC 
frequency 
To elucidate the impact of Hectd1 loss on homeostatic hematopoiesis, we first investigated the 
hematological parameters in young adult mice. Complete blood count (CBC) analysis and flow 
cytometry of different lineages of blood cells from Hectd1f/f;Vav mice showed largely normal blood 
counts compared with their Hectd1f/f  littermates (Figures S2A and S2B). Total BM cellularity and 
spleen weight were also indistinguishable from controls (Figures S2C and S2D). We then 
characterized the hematopoietic stem and progenitor cells (HSPCs) in the BM and spleen. 
Hectd1f/f;Vav mice showed comparable HSPC frequencies and numbers to those of  Hectd1f/f controls 
(Figures S2E-S2H), ie, long-term stem cells (LT-HSCs, Lin-Sca1+c-Kit+Flk2-CD150+CD48-), 
short-term stem cells (ST-HSCs, Flk2-CD150-CD48- LSK), various multipotent progenitors 
(MPPs) (Lv et al., 2017). Furthermore, we observed no difference in the frequency and number of 
committed progenitor cells in the BM by flow cytometry (Figures S2I and S2J) or functional 
progenitors by colony-forming-cell (CFC) assay (Figure S2K). Interestingly, the spleen of 
Hectd1f/f;Vav mice displayed a significant increase in CMP and MEP progenitors  (Figures S2L and 
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S2M), and accordingly, more CFU-E  and CFU-GM colonies as compared to their Hectd1f/f 
littermates (Figure S2N). Moreover, the cell cycle status or apoptosis in HSCs and MPPs remained 
unchanged (Figures S2O-2Q). These observations indicate relatively normal hematopoiesis in 
young adult Hectd1f/f;Vav mice under homeostatic conditions.  
 
To assess the consequences of Hectd1 loss in HSC function in vivo, we performed competitive 
BM transplantation (BMT) assay by injecting 1×106 total BM cells from Hectd1f/f or Hectd1f/f;Vav 
donor mice (CD45.2) with an equal number of BM cells from competitor mice (CD45.1) into 
lethally irradiated recipients (CD45.1/CD45.2) (Figure 1A). Donor chimerism in the peripheral 
blood (PB) of the recipients was determined by flow cytometry every 4 weeks post-BMT. Of note, 
donor-derived cell percentages from Hectd1f/f;Vav mice were considerably decreased compared 
with control mice as early as 4 weeks, and exhibited a progressive decline over time (Figures 1B 
and 1C), indicating a defect in LT-repopulating HSCs. Hectd1 loss did not affect lineage 
distribution in the transplanted recipients (Figures 1D and S3A-S3D). Importantly, the percentages 
of donor-derived HSPC populations from Hectd1f/f;Vav mice were substantially decreased in 
comparison to Hectd1f/f controls (Figure1E), indicating a reduction in HSC reconstitution. To 
further examine the impact of Hectd1 loss on HSC self-renewal, we performed secondary BMT 
by injecting 1×106 total BM cells from primary transplanted mice into secondary recipients. 
Defective reconstitution from Hectd1f/f;Vav mice was further exacerbated in secondary 
transplantation (Figure 1F). Thus, these data indicate that Hectd1f/f;Vav mice have inferior long-
term BM repopulating HSCs with reduced self-renewal. 
 
To functionally quantify HSC frequency, we next employed limiting dilution BMT (Figure 1G). 
A graded dose of BM cells from Hectd1f/f and Hectd1 f/f;Vav mice mixed with a fixed number of 
competitor cells were transplanted into lethally irradiated recipient mice. 16 weeks after BMT, 
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mice with donor percentage higher than 1% were defined as “positive reconstitution” (Bersenev 
et al., 2008). We found that Hectd1f/f;Vav mice harbored a 4-fold reduction in functional HSC 
frequencies in the BM by ELDA analysis (extreme limiting dilution analysis) (Figure 1H) (Hu and 
Smyth, 2009). Hectd1f/f;Vav BM cells exhibited consistently reduced donor chimerisms in the 
recipients transplanted at all doses of donor cells (Figures 1I and S3E-S3G). Since HectD1 was 
reported to be involved in protein secretion and cell migration (Duhamel et al., 2018), we asked if 
Hectd1 loss could affect BM niche or in a cell extrinsic manner. Therefore, we performed 
reciprocal BMT by injecting BM cells from wildtype mice (CD45.1) into Hectd1f/f or Hectd1f/f;Vav 
mice as recipients (CD45.2) (Figure S3H). Donor chimerism as well as lineage distribution in the 
PB and HSPCs in the BM were comparable among recipients of both genotypes (Figures S3I-S3K). 
Taken together, our data provide strong evidence that Hectd1 insufficiency reduces frequencies of 
functional HSCs in the BM.  
 
Hectd1 insufficiency diminishes HSC reconstituting activity in vivo and HSC growth ex vivo  
To further address if the decreased repopulation observed in total BM transplantation is due to 
intrinsic HSC properties, we purified LT-HSCs (LSK CD150+CD48-) from Hectd1f/f and Hectd1 
f/f;Vav mice by flow cytometric sorting and transplanted 100 HSCs into each lethally-irradiated 
recipient along with Sca1-depleted BM competitors (Figure 2A) (Balcerek et al., 2018). Our results 
demonstrated that Hectd1-deficient HSCs exhibited inferior reconstitution ability to that of control 
HSCs in vivo (Figure 2B). Importantly, donor-derived HSPCs in the BM of recipient mice 
transplanted with Hectd1-deficient HSCs were significantly reduced when compared with those 
from control HSCs (Figure 2C), indicating Hectd1 insufficiency decreases intrinsic HSC activity.  
 
We next analyzed the influence of HectD1 on the maintenance of HSC function upon ex vivo 
culture. Purified HSCs were cultured in media containing a combination of cytokines SCF, TPO, 
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FLT3L and IL6 for 12 days. The resultant cultured cells from 100 HSCs were transplanted (Figure 
2A). Our data revealed that Hectd1 insufficiency failed to maintain HSCs ex vivo, which was 
accompanied by a marked reduction in reconstituting capacity (9.0% cultured HSCs vs 57.8% 
fresh HSCs reconstitution at 16 weeks), while control HSCs showed comparable reconstitution 
after culture (92.0% cultured HSCs vs 82.0% fresh HSCs) (Figure 2D). Moreover, examination of 
donor-derived HSPCs in the BM of recipient mice revealed that Hectd1-deficient HSCs 
completely lost their stem cell identity in culture (Figure 2E). Importantly, we found that Hectd1-
deficient HSCs had a visibly slower growth rate than control HSCs ex vivo as determined by 
enumeration of cell numbers, and this phenotype persisted irrespective of cytokines used in culture 
(Figures 2F-2I). Taken together, our data suggest that HectD1 is critical for HSC function in vivo 
and HSC growth ex vivo. 
 
Since HectD1 is widely expressed in a range of hematopoietic cells, we asked if HectD1 is 
preferentially required for HSC function. To test this, we injected 500 purified HSCs (LSK 
CD150+CD48-) or 5000 MPPs/ hematopoietic progenitors (HPCs) (LSK CD150-CD48+) (Oguro 
et al., 2013; Pietras et al., 2015; Wilson et al., 2008) from Hectd1f/f and Hectd1 f/f;Vav mice into each 
sub-lethally irradiated recipient and analyzed donor chimerism every week post-BMT (Figure 2J). 
Of note, our results showed that Hectd1 deficiency markedly decreased HSC reconstitution ability, 
but not that of MPP/HPCs (Figures 2K, 2L and S3L, S3M), indicating that HectD1 plays a critical 
role in regulating HSC function.  
 
HectD1 interacts with, ubiquitinates and regulates the stability of ZNF622  
To study the mechanisms underlying the reduced growth of Hectd1-deficient HSPCs, we first 
evaluated known signaling pathways important for HSC function, ie, JAK-STAT, PI3K-AKT, 
MAPK-ERK, mTOR, GSK3 and β-catenin pathways (Figure S4A). However, none of these 
 
 9 
signaling molecules were altered, except for a significant reduction of phospho-RPS6 (pRPS6) in 
both freshly isolated and cultured Hectd1-deficient LSK cells (Figures 3A and S4B).  
 
To facilitate downstream biochemical studies, we resorted to cytokine-dependent human 
progenitor cell line, TF-1 cells. Using two different shRNAs to stably deplete HECTD1 in human 
TF-1 cells, in comparison to Luciferase (Luc) control (Figure 3B), we observed a significant 
growth retardation in the presence of TPO or GM-CSF upon HECTD1 knockdown (Figures 3C 
and 3D), consistent with findings from HSPCs (Figures 2F-2I). TF-1 cells also recapitulated the 
signaling defects observed in primary LSK cells, which is a reduction in RPS6 phosphorylation 
but not any other pathways we examined (Figures S4C-S4E). Thus, TF-1 cells appear to be a 
reliable and robust cell system for us to further dissect HectD1 functions. 
 
Intriguingly, the reduction of pRPS6 seemed to be independent of mTOR pathway since p-mTOR, 
p4E-BP1, pS6K1 and a S6K1 substrate pZRF (Barilari et al., 2017) were not changed (Figures 3A 
and S4B). This led us to hypothesize that HectD1 might directly ubiquitinate RPS6 or regulate 
S6K1-RPS6 interaction as K63-ubiquitination is known to affect protein complex formation 
(Shembade and Harhaj, 2015). However, neither RPS6 ubiquitination nor the S6K1-RPS6 
interaction was impacted by HectD1 E3 dead mutant C2579G (Mut) (Sarkar and Zohn, 2012)  or 
HECTD1 knockdown (Figures S4F-S4H), implying that HectD1 indirectly affects RPS6 
phosphorylation. The phospho-RPS6 has been shown to control the RiBi- (ribosome biogenesis) 
gene transcriptional program (Chauvin et al., 2014). We found that Hectd1-deficient HSCs did not 
exhibit changes in either total RNA level that is predominantly rRNAs or the mRNA level of the 




In an attempt to explore the molecular mechanism underlying the important role for Hectd1 in 
HSCs in a comprehensive and unbiased manner, we set out to identify HectD1 substrates by 
affinity purification of HectD1 interacting protein complex using mass spectrometry (MS). We 
transfected HA-tagged HectD1 or vector alone into HEK293T cells. HectdD1-interacting proteins 
were immunoprecipitated (IP) using anti-HA agarose beads, followed by HA peptide affinity 
elution. Glycine elution after HA elution detected very few bound proteins, and the non-specific 
proteins remained associated with the agarose beads upon boiling in SDS loading buffer, indicating 
the specificity and robustness of HA-affinity purification (Figure 3E). We thus subjected the HA 
eluates to MS analysis along with vector control. Triplicates of IP-MS were performed and results 
were evaluated using the CRAPome (Contaminant Repository for Affinity Purification) analysis 
(Mellacheruvu et al., 2013). We ranked and selected the potential interacting proteins with the 
cutoff of SAINT (Significance Analysis of INTeractome) score ≥0.5 and fold change (FC) ≥3 
(Figure 3F). Gene ontology (GO) analysis revealed a high enrichment of ribosome/translation-
related proteins and proteasome proteins (Figure S5A and Supplementary Table S1), which is in 
agreement with the role of HectD1 as an E3 ubiquitin ligase and regulator of cell growth. 
Additionally, it suggested a potential role for HectD1 in ribosomes and protein synthesis.  
 
Among the top hits, we focused on ZNF622 protein, given the critical role of its yeast homolog 
Rei1 in ribosome biogenesis (Greber et al., 2016; Meyer et al., 2010). The interaction between 
HectD1 and ZNF622 was first confirmed in Flag-ZNF622 reconstituted TF-1 cells by co-IP 
(Figure 3G). Next, we generated a series of deletion mutants of HectD1 and ZNF622, and 
transfected them into 293T cells, followed by IP/WB analysis to map the responsible domain(s) 
for their interaction. Our data showed that Hectd1 interacted with ZNF622 regardless of its E3 
activity as both HA-Hectd1 WT, and E3 dead mutant C2579G (Mut), but not vector control could 
pull down endogenous ZNF622. We also found that the Sad1/UNC domain of HectD1 is 
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responsible for its interaction with ZNF622 (Figures S5B and S5C). Furthermore, deletion of either 
ZnF2 domain or the first linker region (LR1) located in the N-terminus of ZNF622 completely 
abolished its interaction with HectD1 (Figures S5D and S5E). Interestingly, cryo-EM analysis has 
revealed that that these two regions of Rei1 are located outside of the polypeptide tunnel (Greber 
et al., 2016; Kargas et al., 2019),  rendering it accessible to HectD1 interaction.  
 
Next, we asked if HectD1 regulates ZNF622 ubiquitination and protein stability. We found that 
Hectd1 deficiency increased ZNF622 protein, but not mRNA levels in LSK cells (Figures 3H-3J). 
Consistently, ZNF622 protein but not mRNA level was increased in HECTD1-depleted TF-1 cells 
(Figures 3K, 3L and S5F). Importantly, the half-life of ZNF622 proteins was significantly 
prolonged in HECTD1-depleted TF-1 cells in the presence of cycloheximide (CHX) that blocks 
nascent protein synthesis (Figures 3K and 3L). Next, we analyzed ZNF622 ubiquitination status 
impacted by HectD1 using Nickel-beads (Ni-NTA) pulldown of His-tagged Ub under denatured 
conditions to capture direct Ub-conjugation in ZNF622 proteins while reducing the detection of 
its associated proteins. Our data demonstrated that ZNF622 was robustly ubiquitinated by WT 
HectD1, but not the C2579G mutant. Moreover, consistent with the notion of HectD1 being an E3 
ligase for lysine63-polyubiquitination (K63-Ub) (Sarkar and Zohn, 2012), K63R, but not K48R Ub 
mutant, abolished ZNF622 ubiquitination (Figure 3M), further demonstrating that ZNF622 is a 
direct substrate of HectD1. Taken together, our data suggest that HectD1 interacts with, 
ubiquitinates and regulates the stability of ZNF622.  
 
Hectd1 insufficiency decreases HSPC proliferation and global translation rates upon stress  
The HectD1 IP-MS data and the interaction between HectD1-ZNF622 promoted us to investigate 
a potential role for HectD1 in protein synthesis and ribosome biology. To test this, we performed 
in vivo OP-puro (O-propargyl Puromycin) assay in primary adult Hectd1f/f and Hectd1 f/f;Vav mice 
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to evaluate protein synthesis rate (Liu et al., 2012). We found that HSCs exhibited a lower protein 
synthesis rate than restricted progenitors and mature hematopoietic cells (Figures S5G and S5H), 
consistent with the previous report (Signer et al., 2014). However, Hectd1 insufficiency did not 
affect protein synthesis rates in any of the hematopoietic cell subsets at the steady state (Figure 
S5H).  
 
Our data showed that Hectd1 deficiency does not affect phenotypic HSC number in the steady 
state (Figure S2G), but dramatically decreases functional HSCs in the transplantation assay or ex 
vivo culture, both of which conditions force HSCs to proliferate (Figures 1 and 2). Thus, we 
investigated if HectD1 is critical for HSC proliferation in vivo under stress conditions. We 
subjected the mice to two different types of stress. We first challenged Hectd1f/f and Hectd1f/f;Vav 
mice with cytoablative drug 5-fluorouracil (5-FU), which depletes cycling hematopoietic cells and 
drives primitive HSCs to regenerate. At day 10 after 5-FU administration, Hectd1 f/f;Vav mice 
exhibited a pronounced reduction in BM HSC and MPP numbers in comparison to the control 
mice (Figure 4A). Notably, both Hectd1 deficient HSCs and MPPs showed reduced protein 
synthesis rate using the OP-Puro assay (Figures 4B and 4C), which correlated with their slower 
cycling status than the controls as determined by BrdU incorporation (Figure 4D). We did not 
observe elevated cell death under 5-FU stress (Figure S5I). To consolidate the conclusion of 
HectD1 function under stress conditions, we subjected mice to cyclophosphamide treatment 
followed by two daily doses of GCSF to induce HSPC proliferation (Morrison et al., 1997).  In 
agreement, our data revealed lower HSC and MPP numbers (Figure 4E), slower cell cycle kinetics, 
as well as decreased protein synthesis rate in Hectd1 f/f;Vav mice in comparison to the controls 




Next, we examined OP-Puro incorporation in ex vivo cultured LSK cells, which were also 
undergoing proliferative stress. Hectd1-deficient cells displayed a decrease in global translation 
rate by >20% when compared to control LSKs (Figures 4I and 4J). Consistently, Hectd1-deficient 
BM progenitors were hypersensitive to puromycin, an inhibitor of translation elongation (Figure 
4K). Of note, this observed translation defect in both primary LSK cells and TF-1 cells was 
independent of eIF2D or 4E-BP1 phosphorylation, two key regulators of translation initiation 
(Figures S4B-S4E) (Holcik and Sonenberg, 2005). Taken together, we demonstrate that HectD1 
plays a critical role in HSPC proliferation and protein synthesis under hematopoietic stress. 
 
Hectd1 deficiency disrupts ZNF622-mediated 60S ribosome maturation and 60S/40S subunit 
joining 
To dissect molecular mechanisms by which HectD1 regulates ribosome assembly and protein 
translation, we examined whether HectD1 affects ribosome composition by polysome profiling 
assay. Cell lysates of equal RNA content were fractionated in a sucrose gradient, followed by 
recording of the ultraviolet (UV) absorbance of each fraction. Hectd1-null LSK cells displayed an 
increased 60S content but decreased 80S monosome and polysome, while 40S remained 
unchanged (Figure 5A). This phenotype was also observed in HECTD1-depleted TF-1 cells 
(Figure 5B). These data indicated a previously-unrecognized role for HectD1 in regulating 
ribosome assembly and proper global translation.  
 
During ribosome biogenesis, subunits are exported to the cytoplasm as pre-60S and pre-40S 
complexes that must undergo final maturation involving sequential addition and release of a series 
of proteins to form mature 60S and 40S subunits (de la Cruz et al., 2015; Kargas et al., 2019). In 
yeast, ZNF622 homolog Rei1, stabilizes Arx1 (human PA2G4) association with pre-60S (Greber 
et al., 2012). Jjj1 (human DNAJC21) is required for the release of Rei1-Arx1 complex and the 
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completion of polypeptide exit tunnel (PET) maturation (Lo et al., 2010; Meyer et al., 2010). 
Failure of Rei1/Arx1 dissociation from pre-60S particles precludes downstream assembly events, 
including the anti-association factor eIF6 release from pre-60S, which is a crucial step for 40S 
joining to form a functional ribosome. Thus, we sought to test if the elevated ZNF622 level in 
HECTD1-depleted cells would affect 60S maturation. Fractions of shLuc or shHECTD1 TF-1 cells 
from the sucrose gradient were collected and examined by WB. The results showed that HECTD1 
was predominantly located in the cytosol, with a small fraction detected in free ribosome subunits 
(Figure 5C). Notably, ZNF622 was predominantly associated with the 60S, and HECTD1 
depletion resulted in a marked accumulation of ZNF622 in the 60S (Figures 5C and 5D). In 
contrast, the 40S protein Nob1 remained unchanged. Moreover, the ZNF622 binding partner 
PA2G4 and downstream eIF6 were markedly increased in the 60S, indicating an abnormal 60S 
ribosome formation (Figures 5C and 5D). Interestingly, the ribosome biogenesis factor for the 
maturation of the polypeptidyl transferase center (PTC), NMD3, was unchanged (Figures 5C and 
S6), indicating that the regulation of PET and PTC may be uncoupled. Besides the association and 
release of assembly factors, the cytoplasmic maturation of pre-60S subunit involves the 
concomitant incorporation of cytoplasmic ribosome proteins (de la Cruz et al., 2015; Kargas et al., 
2019). Consistent with this notion, we found impaired incorporation of cytoplasmic RPL24 in the 
polysomes of HECTD1-depleted cells (Figures 5C and 5D), whereas other core RPL proteins that 
were pre-assembled in the nucleus, such as RPL11 and RPL23A, were unaffected (Figures 5C and 
S6). Of note, we observed a reduced pRPS6 level but not total RPS6 in HECTD1 deficient cells 
when compared to the controls (Figures 5C and S6). Together, these data suggest that increased 
ZNF622 proteins upon HECTD1 loss leads to a defective 60S maturation or activation of a 
translational quality control pathway arising from a block in the release of PA2G4 and eIF6, 




To gain further insight into the role for HectD1 in the regulation of ZNF622 in 60S formation and 
60S/40S subunit joining, we assessed if depletion of ZNF622 could rescue the ribosome defects 
observed upon HECTD1 loss. We compared the polysome profiling and eIF6 retention in the 60S 
of shLuc control, HECTD1 single and HECTD1; ZNF622 double knockdown (DKD) TF-1 cells 
(Figure 5E). Our data showed that knockdown of ZNF622 in HECTD1-deficient cells restored 
ribosome composition as well as eIF6 release to normal levels (Figures 5F-5H).  Furthermore, we 
performed ribosome dissociation/reassociation assay with these cell lines to directly interrogate 
60S/40S subunit joining (Burwick et al., 2012). 80S monosomes and polysomes were first 
dissociated into 40S and 60S subunits under low Mg2+ conditions, and the total amount of 40S and 
60S was comparable among these three cell lines (Figures 5I and 5J). We subsequently added back 
Mg2+ allow 40S and 60S subunits to reassociate. HECTD1 depletion reduced ribosomal 
reassociation. Importantly, this disruption in ribosomal reassociation was reversed by ZNF622 
knockdown (Figures 5I and 5J). Taken together, these results provide direct evidence that HectD1 
plays an essential role in controlling 60S/40S subunit joining and translational control by 
regulating ZNF622.  
 
ZNF622 depletion restores protein translation and HSC transplantation activity induced by 
Hectd1 loss 
We reasoned that if the compromised translation rate observed in Hectd1-deficient cells was owing 
to the elevated ZNF622 level and ZNF622-mediated ribosome defects, attenuation of ZNF622 
expression would be able to rescue this phenotype. To test this hypothesis, we knocked down 
ZNF622 with shRNA in Luc- or HECTD1-depleted TF-1 cells (Figure 6A). Strikingly, ZNF622-
depletion fully restored protein synthesis rate to normal levels in HECTD1-depleted cells, while it 
did not significantly affect the translation rate in control cells as examined by the OP-Puro assay 
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(Figure 6B). Of note, ZNF622 downregulation restored pRPS6 level in HECTD1-depleted cells 
that was independent of mTOR (Figures 6A and S6G). 
 
We next asked if the aberrant accumulation of ZNF622 accounts for the perturbed HSC activity 
owing to Hectd1 deficiency. To functionally test this, we depleted Znf622 in Hectd1-null HSCs 
and examined their reconstitution ability. We first generated two efficient shRNAs against mouse 
Znf622 (shZnf622#1 and #2) with #1 shRNA being the most robust (Figure 6C). Subsequently, 
LSK cells were purified from Hectd1f/f;Vav mice and infected with lentivirus expressing shLuc or 
two shRNAs to Znf622 with mCherry as a fluorescent marker. We injected 250k lentivirally-
infected LSKs into each recipient with 500k Sca1-depleted competitor BM cells to ensure high 
donor reconstitution and recipient survival (Figure 6D) (Jiang et al., 2012). Both Znf622 shRNAs 
increased the reconstitution of Hectd1-deficient HSCs in the peripheral blood (PB) of the recipient 
mice (Figure 6E). Importantly, mice transplanted with LSKs depleted of Znf622 had a significantly 
higher proportion of mCherry+ cells in the BM HSCs and MPPs than those with shLuc (Figure 6F). 
Therefore, the restored donor chimerism observed in the PB was resulted from HSC restoration.  
 
We next examined if the rescue effect of Znf622 downregulation was specific to Hectd1-null 
background. LSKs from both Hectd1f/f and Hectd1f/f;Vav mice were sorted and infected with 
lentivirus expressing shLuc or shZnf622#1 followed by BMT. While control HSC reconstitution 
in the PB was not significantly affected by Znf622 knockdown, Hectd1-deficient HSC 
reconstitution ability was significantly rescued (Figure 6G), and importantly, that was attributed 
to restored HSPC populations (Figure 6H). Strikingly, mCherry+ donor chimerism in the PB of 
secondary recipients further validated the HSC promoting effect of Znf622 knockdown as the 
reconstitution ability of Znf622-depleted Hectd1-null cells was significantly elevated in 
comparison to control cells (Figure 6I). To summarize, these data support a working model that 
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ZNF622 is an important functional mediator of HectD1 function in regulating ribosome assembly 
and protein translation efficiency, as well as HSC regeneration.  
 
Discussion 
Tightly-regulated protein synthesis rate is critical for HSC maintenance and function, as only a 
30% decrease (using Rpl24Bst/+ mice, where ribosome protein Rpl24 is partially depleted) or 
increase (cKO of Pten or 4E-BP1/2 mice) in protein synthesis is sufficient to impair HSC 
proliferation and self-renewal (Signer et al., 2014; Signer et al., 2016). Here we identified a critical 
role for ubiquitin-dependent regulation of ribosome assembly by HectD1 to meet the increased 
protein demands during HSC regeneration in vivo and ex vivo.  
 
We demonstrate that HectD1 is required for HSC but not progenitor cell expansion in vivo, 
pointing to that balanced protein synthesis is essential for HSC function.  Interestingly, HectD1 is 
dispensable for HSC development during homeostasis, but is critical for HSC regeneration under 
proliferative stress. Of note, HectD1 is found indispensable in all hematopoietic stress conditions 
we tested, such as in vivo transplant settings, ex vivo expansion under cytokines, as well as 
genotoxic stress 5-FU or cyclophosphamide/GCSF-induced HSPC proliferation. The 
extraordinary demands for HSPC growth and proliferation in these conditions require increased 
global protein production, thereby coordinated ribosome production. The data in this report 
suggest that HectD1 controls ribosome assembly and protein synthesis rate during HSC 
regeneration by regulating 60S assembly factor ZNF622. Of note, we cannot exclude the 
possibility that HectD1 also regulates protein synthesis and cell cycle in some, and potentially 




Impaired ribosome function arising from genetic aberrations of RP proteins or assembly factors 
causes a group of human disorders known as “ribosomopathies”, such as SDS. 90% of SDS 
patients harbor mutations in the SBDS gene, which functions with the GTPase EFL1 to facilitate 
the removal of anti-association factor eIF6 from pre-60S ribosomal subunits to allow the assembly 
of 40S and 60S into functional monosomes (Finch et al., 2011; Menne et al., 2007; Warren, 2018; 
Weis et al., 2015). In addition, biallelic mutations in DNAJC21, a maturation factor for the PET, 
cause abnormal accumulation of PA2G4 and eIF6 in pre-60S ribosomal subunits and reduce 60S 
and 40S joining, eliciting an SDS-like phenotype (Dhanraj et al., 2017; Tummala et al., 2016). It 
is noteworthy that DNAJC21 assists the release of ZNF622-PA2G4 from pre-60S, allowing for 
the progression of downstream maturation steps. Thus, our data suggest that Hectd1 deficiency 
recapitulates both the molecular ribosomal abnormalities and the phenotypic perturbations in 
HSCs, reminiscent of SDS. We found that depletion of ZNF622 in HECTD1-deficient cells rescues 
ribosome composition as well as eIF6 release to normal levels, thereby restoring 60S/40S subunit 
joining and protein translation. Notably, it also supports the idea that ZNF622 influences the 
affinity of eIF6 for the ribosome, thereby serving as a quality control step to ensure proper 
ribosome assembly. More importantly, we demonstrate that downregulation of Znf622 rescues 
HSC reconstitution capacity in Hectd1-null mice, implicating ZNF622 inhibition as a potential 
therapeutic strategy for the treatment of BMF disease with defective ribosomes.  
 
It is important to point out that structure-function studies of ribosome biogenesis and assembly 
factors have been most examined in yeast and prokaryotes. Our work provides significant 
biochemical and functional insight into the critical biogenesis factors of human and mouse 
ribosomes. Structural analysis of the yeast homolog of ZNF622, Rei1, revealed that the Rei1 C-
terminus is deeply inserted into the 60S PET, which is essential for the proofreading of PET 
maturation and subsequent Arx1 (yeast PA2G4) liberation and eIF6 eviction steps (Greber et al., 
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2016). Our data in human hematopoietic cells demonstrate that accumulated ZNF622 in pre-60S 
blocks PA2G4 removal and efficient ribosome maturation, in accordance with the function of Rei1 
in Arx1 release in yeast cells (Meyer et al., 2010). An alternative but not mutually-exclusive 
explanation points to a subunit joining and translation defect rather than a biogenesis defect upon 
HECTD1 loss, since the amount of total 40S and 60S was unaffected. In the absence of HECTD1, 
ZNF622 abnormally accumulates in the pre-60S and/or rebinds to mature 60S to block 60S/40S 
joining via ZNF622-associated eIF6. A role for ZNF622 and eIF6 in ribosomal stress and 
translational quality control has been suggested in a whole-genome CRISPRi screen in human 
chronic myeloid leukemia (CML) cell line. This study revealed that depletion of ZNF622 or eIF6 
restores cell fitness and cell growth in the presence of PF8503, a translational inhibitor that binds 
to the PET and inhibits the translation of selective proteins and suppresses cell proliferation (Liaud 
et al., 2019). Hence, our work may uncover a ribosome quality control pathway that is critical for 
HSPCs during regenerative or proliferative stress. Under this circumstance, high demand for 
protein synthesis increases the need for ribosome quality control, where HECTD1 activity controls 
ZNF622 and eIF6-mediated ribosome assembly and protein translation efficiency.  
 
In yeast, Rei1-Arx1 departure from 60S coincides with the exchange for the Rei1 family member 
Reh1 in the PET that persists in the later stages of cytoplasmic maturation process (Kargas et al., 
2019; Ma et al., 2017). This finding is in striking contrast to those reported in yeast, in which dual 
knockout of Rei1 and Reh1 severely constrains yeast cell growth (Greber et al., 2016). Therefore, 
it is possible that ZNF622 exerts a distinct function from its yeast homologs. The N-terminus of 
Rei1 contacts RPL24 on the surface of the 60S ribosome (Greber et al., 2016) and directly interacts 
with eIF6 (Kargas et al., 2019). ZNF622 may regulate eIF6 release through its direct interaction 
with eIF6, or indirectly through RPL24. In agreement, we demonstrate that increased ZNF622 
protein level coincides with an accumulation of eIF6 in the 60S subunit of HECTD1-depleted cells 
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and depletion of ZNF622 reduces eIF6 association in the 60S. Of note, RPL24 is essential for the 
formation of 60S-40S inter-subunit bridges, one of which depends on the direct interaction 
between RPL24 and RPS6 (Kisly et al., 2019). Our data raise the possibility that RPS6 
phosphorylation serves as a feedback regulation in the 40S subunit when the 60S large subunit 
encounters stress, as we observed a correlation between pRPS6 and 60S maturation and protein 
synthesis in this context. Nonetheless, the intricate regulation between different ribosome subunits 
and monosomes/polysomes mandates future investigations. 
 
Taken together, we reveal a ubiquitin-dependent control of ribosome assembly and protein 
synthesis that is essential to HSC activity and regeneration, highlighting the importance of 
ribosome assembly factors in HSC function. Importantly, we demonstrate that Znf622 depletion 
restores 60S ribosome maturation, ribosome assembly, protein synthesis and HSC activity in the 
context of Hectd1 deficiency. This finding establishes an in vivo example of genetic suppression 
of HSC defects associated with dysfunctional ribosomes. Hence, it will likely enhance our 
understanding of the pathogenesis and therapeutic strategies for ribosomopathies. 
 
Limitations of the Study 
Our work demonstrates that the E3 ubiquitin ligase HectD1 plays an important role in HSC 
regeneration by ubiquitin-dependent regulation of ribosome assembly via ZNF622. While our 
study provides strong evidence for HectD1/ZNF622-mediated protein translation in HSPCs under 
stress conditions, it is unclear if they play a role in 60S ribosome biogenesis or quality control of 
stressed ribosomes. We also found that the level of phospho-RPS6 was dramatically decreased in 
Hectd1-deficient cells and this correlates with reduced protein synthesis rate and HSPC function. 
However, we do not understand the underlying mechanism or its relevance to ZNF622. Another 
limitation is that we immunoblotted and quantified the distribution of ribosomal proteins and 
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association factors in ribosomal fractions of a hematopoietic cell line TF-1 cells, but not in HSPCs 
due to their scarcity.   
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Main figure titles and legends 
 
Figure 1. Hectd1-deficient BMs display a defective reconstituting ability and reduced 
functional HSC frequency.  
(A) Experimental scheme of serial BM transplantation assay. 
(B) Representative flow plots of donor/competitor/host chimerism in the peripheral blood (PB) 
of recipient mice after transplantation.  
(C) Donor chimerisms in the PB of recipient mice were measured every 4 weeks and the results 
are graphed. Hectd1f/f (n=11) and Hectd1f/f;Vav (n=11).  
(D) Lineage reconstitutions of donor-derived cells in primary recipients at 16 weeks post-
transplantation are shown. Hectd1f/f (n=11) and Hectd1f/f;Vav (n=11). 
(E) Percentages of donor-derived HSPC subpopulation in the BM of primary transplanted mice 
at 16 weeks are shown. Hectd1f/f (n=6) and Hectd1f/f;Vav (n=6). 
(F) Donor percentages in the PB of secondary BMT recipients were analyzed every four weeks 
and the results are graphed. Hectd1f/f (n=10) and Hectd1f/f;Vav (n=11). 
(G) Experimental scheme of limiting dilution BMT to assess functional HSC frequency of 
Hectd1f/f and Hectd1 f/f;Vav BMs. (H) The results are presented as number of positively engrafted 
mice versus total number of mice analyzed for the indicated doses. Positive engraftment was 
defined as >1% donor-derived cells in the PB. CRU: competitive repopulating unit. 1SE: one 
standard deviation.  
(I) Donor chimerisms in the PB of recipient mice transplanted with different doses of BM cells at 
16 weeks are shown. 100k: Hectd1f/f (n=5) and Hectd1f/f;Vav (n=6); 30k: Hectd1f/f (n=10) and 
Hectd1f/f;Vav (n=13); 10k: Hectd1f/f (n=9) and Hectd1f/f;Vav (n=7).  In all relevant panels, each 
symbol represents an individual mouse; bars indicate mean frequencies; error bars indicate SE. *: 
p<0.05; **: p<0.01; ***: p<0.001; ns: not significant, as determined unpaired by two-tailed 
Student’s t-test. 
See also Figure S1, S2 and S3A-S3K. 
 
Figure2. HectD1 is required for HSC self-renewal in vivo and maintenance ex vivo. 
(A) Experimental scheme of HSC transplantation assay. LT-HSCs (LSK CD150+CD48-) from 
Hectd1f/f and Hectd1 f/f;Vav mice were purified by flow cytometric sorting and 100 HSCs were either 
injected with 500K Sca1-depleted competitor BMs into lethally irradiated recipient mice (Day0-
BMT) or the resultant culture after 12 days was injected with 300K BMs into recipient mice 
(Day12-BMT).  
(B) Donor chimerisms in the PB of recipient mice transplanted with fresh HSCs (day0-BMT) were 
measured every 4 weeks and the results are shown in the graph. Hectd1f/f (n=8) and Hectd1f/f;Vav 
(n=8). 
(C) Percentages of donor-derived HSPC subpopulations in the BM of day0-BMT recipient mice 
16 weeks post-transplant are shown. Hectd1f/f (n=6) and Hectd1f/f;Vav (n=5). 
(D) Donor chimerisms of day12 cultured HSC transplants (Day12-BMT) in the PB of recipient 
mice were measured every 4 weeks and the results are shown in the graph. Hectd1f/f (n=7) and 
Hectd1f/f;Vav (n=5). 
(E) Percentages of donor-derived HSPC subpopulations in the BM of day12-BMT recipient mice 
16 weeks post-transplant are shown. Hectd1f/f (n=6) and Hectd1f/f;Vav (n=4). 
(F) Representative images of ex vivo cultured HSCs at day 8.  
(G-I) Cell numbers of ex vivo cultured HSCs at different time points in different combinations of 
cytokines are shown. n=3 in each group.  
(J) Experimental scheme of HSC versus MPP/HPC transplantation assay. HSCs (LSK 
CD150+CD48-) or MPP/HPCs (LSK CD150-CD48+) were sorted from Hectd1f/f and Hectd1 f/f;Vav 




(K-L) Donor chimerisms in the PB of recipient mice were measured by flow cytometry every week 
post-BMT. Donor chimerisms of HSC (K) and MPP/HPC (L) transplants are shown. Hectd1f/f 
(n=7-9) and Hectd1f/f;Vav (n=6-7). 
Data in (G-I) are represented by meanr SD. In all relevant panels, each symbol represents an 
individual mouse; bars indicate mean frequencies; error bars indicate SE. *: p<0.05; **: p<0.01; 
***: p<0.001, as determined by unpaired two-tailed Student’s t-test. 
See also Figure S3L-S3M. 
 
Figure 3. HectD1 interacts with, ubiquitinates, and degrades ZNF622.  
(A) Freshly purified LSKs from Hectd1f/f and Hectd1 f/f;Vav  mice were used to examine various  
signaling molecules by WB using the indicated antibodies.  
(B) TF-1/hMPL cells stably depleted of HECTD1 using two different shRNAs were generated 
along with shRNA to Luciferase (Luc). Cell lysates were subjected to WB analysis using indicated 
antibodies.  
(C, D) TF-1/hMPL shLuc or shHECTD1 cells were cultured in triplicates in different 
concentrations of GM-CSF (D) or TPO (D). Cell growth after 3 days’ culture were determined by 
MTT absorbance.  
(E) Silver staining gel image of a representative large-scale protein purification result to evaluate 
the efficiency and specificity of affinity purification of HA-HectD1 interacting proteins. * 
indicates the HA-HectD1 bait. IgG-H: indicates the Immunoglobin heavy chain.  
(F) CRAPome analysis of Hectd1-intearacting proteins from three independent IP-MS results 
revealed the SAINT probability over fold changes. ZNF622 was identified as an Hectd1 interactor 
and highlighted in red.  
(G) co-IP/WB analysis confirmed the interaction between Flag-ZNF622 and endogenous HectD1 
in Flag-ZNF622 reconstituted TF-1 cells.  
(H) ZNF622 protein levels were increased in Hectd1 f/f;Vav  LSKs compared to that of Hectd1f/f 
LSKs.  
(I) Quantification of ZNF622 protein levels from three independent experiments as in (H) is plotted.  
(J) ZNF622 mRNA levels were not affected in Hectd1-deficient LSKs as shown by qRT-PCR 
analysis. n=3 in each group. 
(K) TF-1 cells stably depleted of HECTD1 using two different shRNAs were treated with 
cycloheximide (CHX) for indicated times. ZNF622 half-lives were determined by WB. 
Representative blots of 3 independent experiments are shown. S.E., short exposure; L.E., long 
exposure. 
(L) Relative ZNF622 levels normalized to Luc time 0 (left panel) and that normalized to respective 
time 0 (right panel) as shown in (J).  
(M) 293T cells were transfected with HA-HectD1 or E3-dead mutant HectD1, along with Flag-
ZNF622 and His-Ub or Ub mutant constructs as indicated. Cells were subjected to lysis in 
denatured condition followed by Ni2+ beads-pulldown.  Ubiquitinated proteins were detected by 
WB using indicated antibodies.  
In all relevant panels, data are represented by meanr SD. p-values are determined by unpaired 
two-tailed Students’ t-test. *: p<0.05; **: p<0.01; ***: p<0.001 
See also Figure S4. 
 
Figure 4. Hectd1 deficiency reduces HSC frequency and protein translational rate upon 
proliferative stress  
(A-D) Hectd1 f/f and Hectd1 f/f;Vav  mice were injected with 150mg/kg 5-FU, and euthanized at 10 
days later for subsequent analysis.  
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(A) HSC and MPP numbers in the BM of 5-FU challenged Hectd1 f/f (n=8) and Hectd1 f/f;Vav  (n=8) 
mice are shown. 
(B) Representative histogram plot of protein synthesis rate in BM HSCs of 5-FU challenged mice 
as determined by in vivo OP-Puro assay. 
(C) Quantification of protein synthesis rate in HSCs and MPPs of 5-FU challenged Hectd1 f/f (n=6) 
and Hectd1 f/f;Vav  (n=5) mice as shown in (B). 
(D) Percentages of BM HSCs and MPPs in the S phase of the cell cycle as determined by in vivo 
BrdU assay. Hectd1f/f (n=3) and Hectd1 f/f;Vav  (n=3). 
(E-H) Hectd1 f/f and Hectd1 f/f;Vav  mice were injected with cyclophosphamide (Cy) followed by 
two consecutive daily injections of G-CSF. Mice were euthanized one day after the last injection 
for subsequent analysis. 
(E) HSC and MPP numbers in the BM of Cy+2GCSF challenged Hectd1 f/f (n=7) and Hectd1 f/f;Vav  
(n=7) mice. Data are pooled from 4 independent experiments and unique symbols indicate mice 
from different experiments. 
(F) Representative histogram plot of protein synthesis rate in BM HSCs of Hectd1 f/f and Hectd1 
f/f;Vav  mice as determined by in vivo OP-Puro assay. 
(G) Quantification of protein synthesis rate in HSCs and MPPs of Hectd1f/f (n=4) and Hectd1 f/f;Vav  
(n=4) mice as shown in (F). 
(H) Percentages of BM HSCs and MPPs in the S phase of the cell cycle as determined by in vivo 
BrdU assay. Hectd1f/f (n=3) and Hectd1 f/f;Vav  (n=4). 
(I) Protein synthesis rates of 2-day cultured LSKs from Hectd1f/f and Hectd1 f/f;Vav  mice were 
determined by OP-puro incorporation of newly synthesized protein after 1hr labelling.  
Representative histogram plot is shown.  
(J) Quantification of relative protein synthesis rates of 2-day cultured LSKs from three independent 
experiments using OP-Puro assays as shown in (I). 
(K) Relative CFU-GM progenitors from Hectd1f/f (n=3) and Hectd1 f/f;Vav  (n=3) BMs in the 
presence of various concentrations of the translation elongation inhibitor puromycin is shown.  
Data in (A, C, D, E, G and H) are represented by meanr SE. Data in (J, and K) are represented by 
meanr SD. p-value in (E) is determined by paired two-tailed Students’ t-test; p-values in other 
panels are determined by unpaired two-tailed Students’ t-test. *: p<0.05; **: p<0.01; ***: p<0.001; 
ns, not significant. 
See also Figure S5. 
 
Figure 5. Hectd1 deficiency results in an accumulation of ZNF622 and eIF6 in the 60S and a 
reduction in ribosomal subunit joining, which is restored by ZNF622 depletion.  
(A) Polysome profiling analysis of 2 day-cultured LSKs from Hectd1f/f and Hectd1 f/f;Vav  mice.  
(B) Quantifications of 60S:40S ratio (left panel) and 60S:80S ratio (right panel) from polysome 
profiling assay of TF-1 cells expressing shLuc or shHECTD1. Three independent experiments 
were performed. 
(C) Fractions from sucrose gradients (7%-45%) of TF-1 cell lysates stably expressing shLuc or 
shHECTD1 were collected and subjected to WB analysis. Representative result of three 
independent experiments is shown. Fractions 1-3 are cytoplasmic soluble proteins. 40S, 60S, 80S 
monosome and polysome fractions are indicated by colored lines, arrows, and fonts. Whole cell 
lysate (WCL). AF: assembly factor; RPL: ribosome protein large unit; RPS: ribosome protein 
small unit. WCL and sucrose fractions (shLuc and shHECTD1) were resolved in three SDS-PAGE 
gels in parallel. Sucrose fraction immunoblots were processed and developed in parallel, and 
images presented side-by-side.  
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(D) Quantification of relative protein distribution in different polysome fractions as shown in (C). 
Relative protein levels in each fraction was normalized to the peak fraction of the indicated protein 
from the shLuc cells and plotted. n=3-4.  
(E-J) Knockdown of ZNF622 in HECTD1-deficient cells rescues ribosome composition, eIF6 
release, as well as 60S/40S joining. 
(E) WB examination of knockdown efficiency in shLuc, HECTD1 single and HECTD1;ZNF622 
double knockdown (DKD) cells. 
(F) Representative polysome profiles of TF-1 shLuc, HECTD1 and DKD cells. 
(G) Quantifications of 60S:40S ratio (left panel) and 60S:80S ratio (right panel) of polysome 
profiles as shown in (F). n=3. 
(H) Representative result of WB analysis with protein fractions from sucrose gradients (7%-45%) 
of TF-1 shLuc, HECTD1 and DKD cells (top panel). Quantification of eIF6 distribution in 
polysome fractions (bottom panel). N=3. 
(I) Ribosome dissociation/reassociation assay. Indicated TF-1 cell lines were lysed in 0.25mM low 
Mg2+ buffer to dissociate ribosomal subunits (Top graph). MgCl2 was subsequently added to a 
final concentration of 10mM for ribosomal subunit reassociation (Bottom graph). Resultant cell 
lysates were loaded on a 7-45% sucrose gradient profiled. Representative graphs from three 
independent experiments are shown. 
(J) Quantification of 60S:40S ratios in the dissociated profiles (Top panel) and 80S:40S ratios in 
the reassociated profiles (Bottom panel). N=3. Note that the black line (shLuc) and the blue line 
(DKD) in (F, H and I) superimpose.  
All data are represented by meanr SD. p-values are determined by unpaired two-tailed Students’ 
t-test. *: p<0.05; **: p<0.01; ***: p<0.001; ns, not significant. 
See also Figure S6A-S6F. 
 
Figure 6. Knockdown of Znf622 in Hectd1-deficient cells restores protein synthesis rate and 
HSC reconstitution ability.  
(A) TF-1 cells stably expressing control shLuc, single or double knockdown of HECTD1 and 
ZNF622 were generated by lentiviral infection and sorting. WB analysis with indicated antibodies 
is shown.  
(B) Global protein synthesis rates of various TF-1 cells as in (A) were measured using OP-Puro 
assay.  
(C) Knockdown efficiency of 3 different shRNAs to mouse Znf622 in BaF3 cells is shown. shRNA 
#1 and #2 are chosen for subsequent BMT.  
(D) Schematic illustration of HSC lentiviral transduction/BMT strategy.  
(E) mCherry+ donor fractions in the PB were analyzed every 4 weeks post-BMT. Quantifications 
of mCherry+ % within donor from each group are shown. f/f;Vav+shLuc, n=5;  f/f;Vav+shZnf622#1, 
n=6;  f/f;Vav+shZnf622#2, n=5. 
(F) Quantifications of mCherry+ donor% in the HSC and MPP fractions 16-weeks post BMT are 
shown. f/f;Vav+shLuc, n=5;  f/f;Vav+shZnf622#1, n=3;  f/f;Vav+shZnf622#2, n=4. 
(G) In a separate experiment, LSK cells were purified from Hectd1f/f and Hectd1 f/f;Vav  mice, 
infected with lentivirus expressing shLuc or shZnf622#1, and subsequently transplanted. 
Quantifications of mCherry+ donor% in the PB from each group are shown. f/f +shLuc, n=8; 
f/f+shZnf622#1, n=8;  f/f;Vav+shLuc, n=7;  f/f;Vav+shZnf622#1, n=7. 
(H) Quantifications of mCherry+ donor percentages in the HSC and MPP fractions at the end of 
primary BMT are shown. f/f +shLuc, n=8; f/f+shZnf622#1, n=8; f/f;Vav+shLuc, n=7;  
f/f;Vav+shZnf622#1, n=7. 
(I) Two million BM cells from primary transplanted mice were harvested and transplanted into 
each secondary recipient. Quantifications of mCherry+ % within donor from each group in the 
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secondary transplants are shown. f/f +shLuc, n=16; f/f+shZnf622#1, n=13; f/f;Vav+shLuc, n=14; 
f/f;Vav+shZnf622#1, n=9.  
In all relevant experiments, each symbol represents an individual mouse; horizontal lines indicate 
mean frequencies; error bars indicate SE. *: p<0.05; **: p<0.01; ***: p<0.001; ns, not significant, 
as determined by unpaired two-tailed Student’s t-test. 
See also Figure S6G. 
 
 
Supplemental Excel Table titles and legends 
Table S1. Fold enrichment changes and SAINT score for HectD1 interacting proteins by IP/MS. 
Related to Figure 3. 
 









KEY RESOURCES TABLE 
 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies  
Rabbit polyclonal anti-HectD1 Bethyl lab Cat# A302-908A, RRID:AB_10664800 
Rabbit polyclonal anti-ZNF622 Bethyl lab Cat# A304-075A, RRID:AB_2621324 
Rabbit polyclonal anti-NOB1 Bethyl lab Cat# A304-680A, RRID:AB_2620875 
Rabbit polyclonal anti-RPS3 Bethyllab Cat# A303-840A, RRID:AB_2620191 
Rabbit polyclonal anti-RPL23A Proteintech Cat# 16386-1-AP, RRID:AB_2269755 
Rabbit polyclonal anti-RPL24 Proteintech Cat# 17082-1-AP, RRID:AB_2181728 
Rabbit polyclonal anti-eIF6 Proteintech Cat# 10291-1-AP, RRID:AB_2096515 
Rabbit polyclonal anti-NMD3 Proteintech Cat# 16060-1-AP, RRID:AB_2282830 
Rabbit polyclonal anti-DNAJC21 Proteintech Cat# 23411-1-AP, RRID:AB_2879274 
Mouse monoclonal anti-PA2G4 Proteintech Cat# 66055-1-Ig, RRID:AB_11042597 
Rabbit polyclonal anti-RPL11 Abcam Cat# ab79352, RRID:AB_2042832 
Rabbit monoclonal anti-RPL11 Abcam Cat# ab32157, RRID:AB_732117 
Mouse monoclonal anti- GSK3D/E Millipore Cat# 368662-200UG, RRID:AB_2043310 
Mouse monoclonal anti-HSP90 StressMarq  Cat# SMC-107, RRID:AB_854214 
Mouse monoclonal anti-E-Catenin BD Biosciences  Cat# 610153, RRID:AB_397554 
Goat monoclonal anti-Actin Santa Cruz Cat# sc-1616, RRID:AB_630836 
Rabbit polyclonal anti-STAT5 Santa Cruz Cat# sc-835, RRID:AB_632446 
Rabbit monoclonal anti-pY1007/1008-JAK2 Cell Signaling Cat# 3776, RRID:AB_2617123 
Rabbit monoclonal anti-JAK2 Cell Signaling Cat# 3230, RRID:AB_2128522 
Rabbit polyclonal pY694-STAT5 Cell Signaling Cat# 9351, RRID:AB_2315225 
Rabbit polyclonal anti-pS473-AKT Cell Signaling Cat# 9271, RRID:AB_32982 
Rabbit polyclonal anti-AKT Cell Signaling Cat# 9272, RRID:AB_329827 
Mouse monoclonal anti-pT202/204-ERK1/2 Cell Signaling Cat# 9106, RRID:AB_331768 
Rabbit polyclonal anti-ERK1/2 Cell Signaling Cat# 9102, RRID:AB_330744 
Rabbit monoclonal anti-pS2448-mTOR Cell Signaling Cat# 5536, RRID:AB_10691552 
Mouse monoclonal anti-mTOR Cell Signaling Cat# 4517, RRID:AB_1904056 
Mouse monoclonal pT389-S6K1 Cell Signaling Cat# 9206, RRID:AB_2285392 
Rabbit polyclonal anti-S6K1 Cell Signaling Cat# 9202, RRID:AB_331676 
Rabbit monoclonal anti-pS235/236-RPS6 Cell Signaling Cat# 4858, RRID:AB_916156 
Rabbit polyclonal anti-pS240/244-RPS6 Cell Signaling Cat# 2215, RRID:AB_331682 
Rabbit monoclonal anti-RPS6 Cell Signaling Cat# 2217, RRID:AB_331355 
Rabbit monoclonal anti-pT37/46-4E-BP1 Cell Signaling Cat# 2855, RRID:AB_560835 
Rabbit monoclonal anti-4E-BP1 Cell Signaling Cat# 9644, RRID:AB_2097841 
Rabbit polyclonal anti-pS21/9-GSK3D/E Cell Signaling Cat# 9331, RRID:AB_329830 
Rabbit polyclonal anti-eIF2D Cell Signaling Cat# 9722, RRID:AB_2230924 
Rabbit monoclonal anti-E-Tubulin Cell Signaling Cat# 2128, RRID:AB_823664 
Mouse monoclonal anti-GAPDH Cell Signaling Cat# 97166, RRID:AB_2756824 
Rabbit monoclonal anti-HA Cell Signaling Cat# 3724, RRID:AB_1549585 
Mouse monoclonal anti-FLAG M2-HRP Sigma-Aldrich Cat# A8592, RRID:AB_439702 
Digital anti-mouse HRP  Kindle Biosciences  Cat# R1005, RRID:AB_2800463 
Digital anti-Rabbit HRP  Kindle Biosciences  Cat# R1006, RRID:AB_2800464 
CD45.1-FITC BD Biosciences Cat# 553775, RRID:AB_395043 
CD45.1-PE-Cy7 Thermo Fisher Cat# 25-0453-82, RRID:AB_469629 
CD45.1-eF450 Thermo Fisher Cat# 48-0453-82, RRID:AB_1272189 
CD45.2-APC-Cy7 Thermo Fisher Cat# 47-0454-82, RRID:AB_1272175 
CD45.2-Buv395 BD Biosciences Cat# 564616, RRID:AB_2738867 
Gr1-PE Thermo Fisher Cat# 12-5931-83, RRID:AB_466046 
Mac1-APC Thermo Fisher Cat# 17-0112-83, RRID:AB_469344 
B220-PE BD Biosciences Cat# 553090, RRID:AB_394620 
B220-APC Thermo Fisher Cat# 17-0452-83, RRID:AB_469396 
 
 29 
CD4-PE BD Biosciences Cat# 553049, RRID:AB_394585 
CD8a-PE BioLegend Cat# 100707, RRID:AB_312746 
CD3e-FITC Thermo Fisher Cat# 11-0031-82, RRID:AB_464882 
CD3e-PE Thermo Fisher Cat# 12-0031-85, RRID:AB_465498 
Ter119-biotin labeled Thermo Fisher Cat# 13-5921-85, RRID:AB_466798 
Gr1-biotin labeled Thermo Fisher Cat# 13-5931-86, RRID:AB_466802 
Mac1-biotin labeled Thermo Fisher 13-0112-86, RRID:AB_466361 
B220-biotin labeled Thermo Fisher Cat# 13-0452-86, RRID:AB_466451 
CD19-biotin labeled Thermo Fisher Cat# 13-0193-86, RRID:AB_657655 
CD4-biotin labeled Thermo Fisher Cat# 13-0041-86, RRID:AB_466327 
CD5-biotin labeled Thermo Fisher Cat# 13-0051-85, RRID:AB_466340 
CD8a-biotin labeled Thermo Fisher Cat# 13-0081-86, RRID:AB_466348 
Streptavidin-PE-TexasRed Thermo Fisher Cat# SA1017, RRID:N/A 
Streptavidin-APC-Cy7 Thermo Fisher Cat# 47-4317-82, RRID:AB_10366688 
c-Kit-PE BD Biosciences Cat# 553355, RRID:AB_394806 
c-Kit-APC Thermo Fisher Cat# 17-1171-83, RRID:AB_469431 
c-Kit-APC-Cy7 Thermo Fisher Cat# 47-1171-82, RRID:AB_1272177 
ScaI-PE BD Biosciences Cat# 553336, RRID:AB_394792 
ScaI-PerCp-Cy5.5 Thermo Fisher Cat# 45-5981-82, RRID:AB_914372 
CD150-PE-Cy7 BioLegend Cat# 115914, RRID:AB_439797 
CD48-FITC BioLegend Cat# 103403, RRID:AB_313018 
CD48-APC-Cy7 BioLegend Cat# 103432, RRID:AB_2561463 
CD48-AF700 BioLegend Cat# 103426, RRID:AB_10612755 
CD48-APC Thermo Fisher Cat# 17-0481-82, RRID:AB_469408 
Flk2-PE BD Biosciences Cat# 553842, RRID:AB_395079 
CD34-APC Thermo Fisher Cat# 50-0341-82, RRID:AB_10596826 
CD16/32-PE BD Biosciences Cat# 553145, RRID:AB_394660 
Bacterial and Virus Strains 
pCL20.MSCV.mir30.PGK.mCherry Holmfeldt et al., 2016 N/A 
pCL20.MSCV.mir30.PGK.GFP This paper (Replace mCherry 
with GFP) 
N/A 
Chemicals, Peptides, and Recombinant Proteins 
5-Fluorouracil (5-FU) Sigma-Aldrich Cat# F6627 
Cyclophosphamide Baxer Cat# NDC 10019-955-01 
O-Propargyl-Puromycin (OP-Puro) MedChemExpress Cat# HY-15680/CS-6850 
BrdU BD Pharmingen  Cat# 5133284 
Puromycin dihyrdochloride Sigma-Aldrich Cat# P7255 
Insulin Solution Human Sigma-Aldrich Cat# I9278 
10% BSA in IMDM StemCell Technologies Cat# 09300 
L-Glutamine Gibco Cat# 25030-081 
Holo-Transferrin human Sigma-Aldrich Cat# T0665 
E-Mercaptoethanol Sigma-Aldrich Cat# M3148 
Propidium iodide (PI) Sigma-Aldrich Cat# P4170 
DAPI Sigma-Aldrich Cat# D9542 
3% Acetic Acid with Methylene Blue StemCell Technologies Cat# 07060 
Retronectin Takara Cat# T100B 
Cycloheximide Sigma-Aldrich Cat# C7698 
Imidazole Acros Organics Cat# 288-32-4 
N-Ethylmaleimide (NEM)  Sigma-Aldrich  Cat# E1271 
PR619  LifeSensors  Cat# SI9619 
1,10-phenanthroline Mallinckrodt Chemicals  Cat# 2631-55 
Sodium Fluoride Sigma-Aldrich Cat# S7920 
Sodium orthovanadate Sigma-Aldrich Cat# 450243 
PMSF Sigma-Aldrich Cat# P7626 
Protease Inhibitor Cocktail Tablets; EDTA-free Roche Cat# 11836170001 
Protease Inhibitor Cocktail Tablets Roche Cat# 11697498001 
Bovine Serum Albumin (BSA) Fisher Bioreagents Cat# BP1600 
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Nonfat milk Santa Cruz Cat# sc2325 
StemSpan SFEM StemCell Technologies Cat# 09600 
Fetal Bovine Serum SAFC Biosciences Cat# 12103C 
Bovine Calf Serum HyClone Cat# SH30072.03 
HA peptide Thermo Fisher Cat# 26184 
Anti-HA Affinity Gel Sigma-Aldrich Cat# E6779 
Anti-FLAG M2 Affinity Gel Sigma-Aldrich Cat# F2426 
Protein A Sepharose CL-4B GE Health Cat# 17-0780-01 
Protein G Sepharose 4 Fast Flow GE Health Cat# 17-0618-01 
HisPur Ni-NTA Resin Thermo Fisher Cat# 88221 
Murine SCF Peprotech Cat# 250-03 
Murine Tpo Peprotech Cat# 315-14 
Murine IL3 Peprotech Cat# 213-13 
Murine FLT3L Peprotech Cat# 250-31L 
Murine IL6 Peprotech Cat# 216-16 
rh EPO Espogen Cat# NDC 55513-144-10 
rG-CSF (Neupogen) Amgen Cat# NDC 55513-209-01 
Human GM-CSF Peprotech Cat# 300-03 
Human TPO Peprotech Cat# 300-18 
Critical Commercial Assays 
Lineage Cell Depletion Kit mouse Miltenyi Biotec Cat# 130-090-858 
Anti-Sca-1 Microbead Kit (FITC) Miltenyi Biotec Cat# 130-092-529 
Click-iT Plus OP-Puro Protein Synthesis Kit Thermo Fisher Cat# C10458 
FITC Annexin V Apoptosis Detection Kit BD Pharmingen Cat# 556547 
BrdU Flow Kits BD Pharmingen Cat# 557891 
BD Cytofix/Cytoperm BD Biosciences Cat# 554714 
SYBR Green Master Mix Applied Biosystems Cat# 43-091-55 
RNeasy Plus Mini Kit QIAGEN Cat# 74136 
qScript cDNA Supermix Quanta Biosciences Cat# 98047 
Experimental Models: Cell Lines 
TF-1 ATCC Cat# CRL-2003, RRID:CVCL_0559 
HEK293T ATCC Cat# CRL-3216, RRID:CVCL_0063 
WEHI-3B Dr. Harvey Lodish lab RRID:CVCL_2239 
BaF3  DSMZ Cat# ACC-300, RRID:CVCL_0161 
Experimental Models: Mouse Strains 
C57B6/NGpt-Hectd1tm1b/Gpt EuComm and MARC, China Cat# 5757216, RRID:MGI:5757216 
FLP B6;SJL-Tg(ACTFLPe)9205Dym/J Jackson laboratories Cat# JAX:003800, RRID:IMSR_JAX:003800 
 
Vav-Cre mice Stadtfeld and Graf, 2005; Chen 
et al., 2009 
N/A 
C57BL/6J (CD45.2) Jackson laboratories Cat# 000664 
SJL (CD45.1) Jackson laboratories Cat# 000686 
Oligonucleotides 
sh human HECTD1#1: tatgaaacaagattgtagtcaa  This paper  N/A 
sh human HECTD1#2: taccactggttgttcaactcta This paper N/A 
sh human ZNF622#1: atcggaaagtggagatgatgaa  This paper N/A 
sh human ZNF622#2: tggagacgattgggaagatatt  This paper N/A 
sh mouse Znf622#1: agagaaagttggtgttggcaaa  This paper N/A 
sh mouse Znf622#2: tgtgacagttgctaggaatcaa This paper N/A 
Oligonucleotides for mouse genotyping and 
real-time qPCR see Table S2 
This paper N/A 
Recombinant DNA 
pCMV-HA-HectD1 WT Sarkar and Zohn, 2012 N/A 
pCMV-HA-HectD1 C2579G Sarkar and Zohn, 2012 N/A 
pCMV-HA-HectD1 truncates/deletion mutants This paper N/A 
pOZ-FH-ZNF622 full length  This paper N/A 
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pOZ-FH-ZNF622 truncates/deletion mutants This paper N/A 
pOZ-Flag-ZNF622 This paper N/A 




GraphPad Prism http://www.graphpad.com/ RRID:SCR_002798 
Fiji http://fiji.sc RRID:SCR_002285 
QuantStudio Real-Time PCR software Thermo Fisher https://www.thermofisher.com/us/en/home/life-
science/pcr/real-time-pcr/ 
SAINT Choi et al., 2012 http://saint-apms.sourceforge.net/ 
Main.html 
ELDA Hu and Smyth, 2009 http://bioinf.wehi.edu.au/software/elda/ 









Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Wei Tong (tongw@chop.edu). 
 
Materials Availability 
This study did not generate new unique reagents. 
 
Data and Code Availability 
This study did not generate new datasets.  
 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
Mouse models 
Hectd1 “knockout-first, conditional-ready” mouse line (C57B6/NGpt-Hectd1tm1a/Gpt, #T000502) 
was obtained from EuComm (the ES lines were generated by European Consortium) and Model 
Animal Resource Information Platform of Nanjing University, China. FLP1 recombinase 
transgenic mice (B6;SJL-Tg(ACTFLPe)9205Dym/J, #003800) and SJL (CD45.1) recipient 
mice were purchased from the Jackson Laboratory (Rodriguez et al., 2000). Vav1-Cre mice were 
originally generated by Dr. Thomas Graf (Stadtfeld and Graf, 2005) and generously provided by 
Dr. Nancy Speck (Chen et al., 2009). Hectd1 transgenic mice were first crossed with Rosa-
Flippase mice to eliminate FRT-flanked LacZ and Neo mini-gene, and then with wild type mice 
to get rid of the Rosa-Flippase gene to minimize the possible effects of these elements in 
hematopoiesis. The resultant mice with loxP-flanked Hectd1 alleles (Hectd1f/f) targeting exon 3 
were crossed with Vav-cre transgenic mice to obtain the control Hectd1f/f and Hectd1f/f;Vav 
conditional knockout mice (cKO). All mice were bred and grown in house in pathogen-free animal 
facilities. Both male and female mice (8~12 weeks old) were used and randomly assigned for all 
experiments. All the animal studies were performed under an approved protocol by the 
Institutional Animal Care and Use committee of the Children’s Hospital of Philadelphia. 
 
For 5-FU challenge, sex and age-matched (8~12 weeks old) adult Hectd1f/f and Hectd1f/f;Vav mice 
were injected intraperitoneally with 5-Fluorouracil (5-FU, Cat#F6627, Sigma, 150mg/kg body 
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weight, pH8.5 in PBS) (Rozenova et al., 2015). Total BM cell count, HSC frequency, cell cycle 
and apoptosis assay were determined after 10 days of 5-FU administration. For Cy/GCSF induced 
stress, we intraperitoneally injected mice with 1 dose of cyclophosphamide (4mg/mouse, Baxer) 
followed by two daily subcutaneous injections of 5ug GCSF (Neupogen, Amgen). 1 day after the 
last GCSF injection, mice were euthanized for subsequent analysis (Morrison et al., 1997; Signer 
et al., 2014). 
 
Cell lines  
TF-1 cell lines were purchased from American Type Culture Collection (ATCC) and grown in 
RPMI-1640 media supplemented with 10% bovine calf serum (Cat# SH30072.03, HyClone), 2mM 
L-glutamine (Cat# 25030-081, Gibco) and penicillin/Streptomycin (Gibco) and 2ng/mL GM-CSF 
(PeproTech) at 37°C and 95% humidity in an atmosphere of 5% CO2. 293T cells were from ATCC 
and grown in DMEM media supplemented with 10% bovine calf serum, 2mM L-glutamine and 
penicillin/Streptomycin at 37°C and 95% humidity in an atmosphere of 5% CO2. BaF3 cells were 
maintained in RPMI-1640 media supplemented with 10% bovine calf serum and 10% WEHI 





Genotyping and qPCR 
Mouse tail genomic DNAs were isolated with the standard proteinase K lysis protocol. Genotyping 
was performed by PCR. To evaluated Vav-cre excision efficiency in hematopoietic stem and 
progenitor cells, we plated total BM cells into M3434 methylcellulose semisolid media (StemCell 
Technologies Inc) for colony formation. Single colonies were picked, resuspended in 90uL buffer 
(50mM NaOH, 0.2mM EDTA), and boiled for 20min, followed by mixing with 10uL 1M Tris, 
pH8.0 for neutralization. The lysates were subsequently used for genotyping. Sequences of 
genotyping primers are listed in Table S2. 
 
For quantitative real time PCR assay, total RNA was extracted using RNeasy Mini Kit (Qiagen). 
Reverse-transcription reaction was performed with random primers using qScript cDNA Supermix 
(Quanta Biosciences), and quantitative PCR was done with SYBR Green Master Mix (Applied 
Biosystems). Sequences of qPCR primers are listed in Table S2. 
 
Constructs and virus packaging  
pCMV-HA-HectD1 WT or C2579G mutant constructs were kindly gifted by Dr. Irene E. Zohn  
(Children’s Research Institute, United States, Washington, DC, United States) (Sarkar and Zohn, 
2012). The truncation mutants were amplified by PCR and subcloned into pCMV-HA vector. 
Human ZNF622 cDNA was amplified by PCR from a homemade cDNA library from TF-1 cells 
and constructed into a retroviral pOZ-FH vector that contains a Flag and a HA tag. All the deletion 
or truncation mutants were subcloned into the pOZ-FH vector. HectD1 or ZNF622 miR30-based 
shRNA constructs were subcloned into Lentiviral vector (pCL20.MSCV.mir30.PGK.mCherry) 
generously provided by Dr. Shannon McKinney-Freeman  
 
Complete blood count (CBC), flow cytometry of HSPCs and lineage cells 
Peripheral blood was collected from 8~12 week-old Hectd1f/f and Hectd1f/f;Vav mice into EDTA-
coated tubes. CBC analysis was performed with a Hemavet 950 (Drew Scientific, Inc). For lineage 
staining, cells from peripheral blood were lysed with RBC lysis buffer (0.8% NH4Cl, 10uM EDTA, 
pH 7.4~7.6) for 10min at 4ºC to remove red blood cells, followed by staining with different 
fluorochrome-conjugated anti-Gr-1 (RB6–8C5) (granulocytes), -Mac1 (M1/70) (macrophages), -
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B220 (RA3–6B2) (mature B cells), -CD4 (GK1.5) and -CD8 (53–6.7) (T cells) antibodies, for 
30min at 4ºC. After washing with flow buffer (PBS containing 0.5% BSA), cells were suspended 
in flow buffer containing 1ug/mL propidium iodide (PI) or 2.5ug/mL DAPI for flow cytometry 
analysis. 
 
HSPCs staining was conducted as described previously (Lv et al., 2017). Cells from BM (2 
femurs+2 tibias+2 hips for one mouse) or spleen were harvested in PBS containing 0.5% BSA, 
and quickly lysed with RBC lysis buffer for 1min at 4ºC. Cells were then stained with biotin-
conjugated anti-Gr-1 (RB6–8C5), -Mac1 (M1/70), -B220 (RA3–6B2), -CD19 (eBio1D3), -Ter119 
(TER-119), -CD5 (53–7.3), -CD4 (GK1.5), -CD8 (53–6.7), in combination with APC-Cy7-c-Kit 
(2B8), PerCP-Cy5.5-Sca1 (E13–161.7 or D7), FITC-CD48 (HM48–1), PE-Cy7-CD150 (TC15–
12F12.2), APC-CD34 (RAM34), and PE–Flk2 (A2F10.1) antibodies for 30min on ice, followed 
by secondary staining with streptavidin-PE-TexasRed (Invitrogen SA1017, 1:50) for 30min on ice. 
Different HSPC subpopulations were defined as long-term stem cells (LT-HSCs, Lin-Sca1+c-
Kit+Flk2-CD150+CD48-), short-term stem cells (ST-HSCs, Flk2-CD150-CD48- LSK), multiple 
potent progenitors (megakaryocyte/erythroid-biased MPP2, Flk2-CD150+CD48+ LSK; myeloid-
biased MPP3, Flk2-CD150-CD48+ LSK; lymphoid-biased MPP4, Flk2+CD150-LSK) (Pietras et al., 
2015). 
 
For committed progenitor cell staining, namely granulocyte-monocyte progenitor (GMP, 
CD34+CD16/32+ Lin-c-Kit+Sca1-) cells, common myeloid progenitor (CMP, CD34+CD16/32- 
LKS-) cells and megakaryocyte-erythrocyte progenitor (MEP, CD34+CD16/32- LKS-), cells from 
the BM or spleen were stained with PE-FrRIII/II (CD16/CD32) for 30min on ice after a quick 
RBC lysis, followed by blocking with rat serum, then stained with biotin-conjugated lineage panel 
as described above, along with APC-Cy7-c-Kit (2B8), PerCP-cy5.5-Sca1 (E13–161.7 or D7), 
APC-CD34 for 1h on ice.  
 
Lineage cell FACS samples were analyzed on a BD FACS Canto flow cytometer, while HSPC 
and progenitor samples were analyzed on a BD FACS Fortessa flow cytometer. Data were 
analyzed on FlowJo (FlowJo, LLC). 
 
Competitive BMT and limiting dilution BMT 
For competitive BMT, 1 million total BM cells from 8~12-week-old Hectd1f/f or Hectd1f/f;Vav 
(CD45.2) mice were mixed with the same number of competitor total BM cells (CD45.1), and 
transplanted into lethally irradiated (a split dose of 10Gy) recipient mice (CD45.1/2) by retro-
orbital injection. Every four weeks after BMT, donor cell reconstitution in periphery blood (PB) 
was evaluated by flow cytometry. 16 weeks after BMT, reconstituted donor stem and progenitor 
cells (HSPCs) from BM or spleen were analyzed by flow cytometry. 
 
For limiting dilution BMT, an increasing number (10k, 30k, 100k) of total BM cells from Hectd1f/f 
or Hectd1f/f;Vav (CD45.2) mice were mixed with a fixed number (300k) of competitor BM cells and 
transplanted into lethally irradiated recipient mice (Bersenev et al., 2008). 16 weeks after BMT, 
donor cell percentage in the PB was evaluated by flow cytometry. Mice with more than 1% of 
donor-derived cells were defined as “positive”. Data were analyzed by ELDA (Hu and Smyth, 
2009). 
 
HSC sorting and transplantation 
HSC purification and BMT were performed as described previously (Balcerek et al., 2018). 
Lineage positive cells were first depleted using a lineage cell depletion kit (Cat# 130-090-858, 
Miltenyi Biotec). Lineage negative (Lin-) cells were then stained with APC-Cy7-c-Kit (2B8), 
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PerCP-Cy5.5-Sca1 (E13–161.7 or D7), FITC-CD48 (HM48–1), PE-Cy7-CD150 (TC15–12F12.2). 
LT-HSCs were purified with MoFlo Astrios Sorter and 100 LT-HSCs were seeded in a round-
bottom 96-well plate. These LT-HSCs were either transplanted on the day (D0 BMT) or cultured 
in SFEM media supplemented with 100 ng/mL SCF and 20 ng/mL TPO for 12 days, and all the 
resultant cells were then transplanted (Day12 BMT).  Specifically, 100 LT-HSCs (D0 BMT) or 
100 LT-HSCs-derived cells (CD45.2) at day12 (D12 BMT) were mixed with 500k Sca1-depleted 
competitor BM cells (CD45.1 or CD45.1/2) and injected retro-orbically into lethally irradiated 
(10Gy) recipient mice (CD45.1/2 or CD45.1). Every four weeks after BMT, donor cell 
reconstitution in the PB was evaluated by flow cytometry. 16 weeks after BMT, reconstituted 
donor stem and progenitor cells (HSPCs) from BM or spleen were analyzed by flow cytometry. 
 
OP-Puro (O-propargyl-puromycin) Click-iT protein synthesis assay  
To detect protein synthesis rate in vivo, primary or stressed mice were injected intraperitoneally 
with OP-Puro (Cat# HY-15680, MCE; 50mg/kg body weight, pH6.4-6.6 in PBS) for 1 hour before 
euthanasia (Signer et al., 2014). Total BM cells were harvested and live stained with cell surface 
markers for HSCs/MPPs after a quick RBC lysis. Cells were then fixed with BD Cytofix solution 
for 20min on ice. After washing with BD Perm/Wash buffer, cells were permeabilized with BD 
Cytoperm Plus solution for 10min on ice, followed by refixing in Cytofix solution for 5min. The 
azide-alkyne reaction was performed using Click-iT plus OPP Alexa Fluor 647 or 488 kit (Cat# 
C10458, Invitrogen) for 30min at room temperature.  Cells were then washed and resuspended in 
flow buffer, and analyzed by on a BD FACS Fortessa flow cytometer. 
 
For ex vivo analysis, OP-Puro was added to cell culture at the final concentration of 20uM for 1 
hour at a 37°C incubator. The azide-alkyne reaction was performed as described above. 
 
Cell cycle and cell apoptosis assay 
For BrdU cell cycle analysis, mice were injected with 200uL BrdU (10mg/mL, Cat# 550891, BD 
Pharmingen) for 2 hours. Total BM cells were stained with cell surface markers for HSCs/MPPs, 
and then fixed and permeabilized with BD Cytofix/Cytoperm kit, followed by treatment with 
300ug/mL DNaseI for 1 hours at a 37°C water bath. After washing with BD Perm/Wash buffer, 
cells were stained with FITC-anti-BrdU (Cat# 5133284, BD Pharmingen) for 20min at room 
temperature. After washing, cells were resuspended in flow buffer with DAPI (5ug/mL), and 
analyzed by flow cytometry. 
 
For apoptosis assay, total BM cells were stained with cell surface markers for HSCs/MPPs. After 
washing with flow buffer, cells were resuspended in 200uL Annexin V binding buffer. 10uL FITC-
Annexin V (Cat# 55647, BD Pharmingen) and DAPI were added for 15min at room temperature 
in the dark, followed by adding 800uL binding buffer. Samples were analyzed on a BD Fortessa 
cytometer within 1 hour. 
 
Viral transduction of LSK cells and transplantation 
For LSK lentiviral infection and rescue BMT, sorted LSK cells from either Hectd1f/f or Hectd1f/f;Vav 
(CD45.2) mice were cultured in SFEM media (StemCell Technologies Inc) supplemented with 10% 
FBS (SAFC Biosciences) and cytokines (100 ng/mL mSCF, 20 ng/mL mTpo, 20 ng/mL FLT3L, 
20 ng/mL IL6) for 2 days. Lentivirus carrying mCherry/shLuc or mCherry/shmZNF622 were 
preloaded twice into a RetroNectin (T100B, Takara)-coated 12-well plate (Modlich et al., 2009).  
Cultured LSKs were transferred to the lentivirus-preload plates and incubated for one more day. 
At day3, 250k cultured LSKs were mixed with 500k Sca1-depleted competitor BM cells and 
injected into lethally-irradiated recipient mice.  A small fraction of infected cells was spared for 





For each anti-HA immunoprecipitation, ten ~80% confluent 10cm dishes of 293T cells were 
transiently transfected with pCMV-HA empty vector (control) or pCMV-HA-HectD1. 48 hours 
after transfection, cells were lysed with IP buffer (10mM Tris, pH7.4, 150mM NaCl, 0.5% NP-40, 
1mM NaF, 1mM Na3VO4, PMSF, protease inhibitor cocktail, 10 μM PR-619 (LifeSensors), 4mM 
1,10-phenanthroline (o-PA; Mallinckrodt Chemicals), 4mM N ethylmaleimide (NEM; Sigma-
Aldrich)) for 30 min at 4ºC. Cell lysates were clarified by centrifugation at 13, 000 rpm for 10 min 
at 4°C, and then pre-cleared with protein A/G beads for 30 min.  
 
HA-EZ Agarose beads (E6779, Sigma) were prepared by being sequentially washed with 0.1M 
pH2.5 Glycine, twice in 1M pH8.0 Tris buffer, and twice in IP buffer. Precleared supernatants 
were incubated with 100uL washed HA-EZ Agarose beads for 4 hrs with gentle agitation. We 
transferred the IPs to BioRad Micro Bio-Spin Chromatography Columns (Cat# 732-6204), and 
washed columns with 1mL IP buffer for four times, followed by a quick spin down to drain the 
leftover IP buffer. We then seal the bottom of the columns with parafilm, and added 50uL 1mg/mL 
HA peptides (#26184, Thermo Fisher Scientific) for 15 min at 30°C with occasional mixing, and 
collected the elute as “HA elute1”. This step was repeated to get another 50uL HA peptide eluate 
as “HA elute2”. Then the beads were incubated with 50uL of 0.1M pH2.5 Glycine for 5 min at 
room temperature twice to get “Glycine elute 1 and 2”, which was neutralized with 5uL pH8.0 
Tris. Lastly, the beads were boiled in 75uL 1*LDS loading buffer. All elutes from above were 
added with 25uL 3* LDS loading buffer and boiled for 5min. A small aliquot of eluted samples 
was resolved with SDS-PAGE, and evaluated by silver staining. Once determined the purification 
was successful, we loaded majority of the first HA eluates on an SDS-PAGE, stained with colloidal 
blue. Gel slices were excised and subsequently subjected to mass spectrometry analysis at the 
Harvard Taplin Mass Spectrometry facility. 
 
Mass spectrometry and Significance analysis of INTeractome (SAINT) 
Excised gel bands were cut into approximately 1 mm3 pieces.  Gel pieces were then subjected to a 
modified in-gel trypsin digestion procedure (Shevchenko et al., 1996).  Gel pieces were washed 
and dehydrated with acetonitrile for 10 min, followed by removal of acetonitrile.  Pieces were then 
completely dried in a speed-vac.  Rehydration of the gel pieces was with 50 mM ammonium 
bicarbonate solution containing 12.5 ng/µl modified sequencing-grade trypsin (Promega, Madison, 
WI) at 4ºC.  After 45 min, the excess trypsin solution was removed and replaced with 50 mM 
ammonium bicarbonate solution to just cover the gel pieces.  Samples were then placed in a 37ºC 
room overnight.  Peptides were later extracted by removing the ammonium bicarbonate solution, 
followed by one wash with a solution containing 50% acetonitrile and 1% formic acid.  The 
extracts were then dried in a speed-vac (~1 hr).  The samples were then stored at 4ºC until analysis.   
 
On the day of analysis, the samples were reconstituted in 5-10 µl of HPLC solvent A (2.5% 
acetonitrile, 0.1% formic acid).  A nano-scale reverse-phase HPLC capillary column was created 
by packing 2.6 µm C18 spherical silica beads into a fused silica capillary (100 µm inner diameter 
x ~30 cm length) with a flame-drawn tip (Peng and Gygi, 2001).  After equilibrating the column 
each sample was loaded via a Famos auto sampler (LC Packings, San Francisco CA) onto the 
column.    A gradient was formed and peptides were eluted with increasing concentrations of 
solvent B (97.5% acetonitrile, 0.1% formic acid).   
 
Eluted peptides were subjected to electrospray ionization and then entered into an LTQ Orbitrap 
Velos Pro ion-trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA).  Peptides were 
detected, isolated, and fragmented to produce a tandem mass spectrum of specific fragment ions 
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for each peptide.  Peptide sequences (and hence protein identity) were determined by matching 
protein databases with the acquired fragmentation pattern by the software program, Sequest 
(Thermo Fisher Scientific, Waltham, MA) (Eng et al., 1994).  All databases include a reversed 
version of all the sequences and the data was filtered to between a one and two percent peptide 
false discovery rate.    
 
We performed 3 biological replicates of IP-MS. Three replicates were evaluated by CRAPome 
(v1.1) (Contaminant Repository for Affinity Purification) analysis (http://www.crapome.org/) 
(Mellacheruvu et al., 2013). We used five HA controls with four (CC51, CC52, CC53, CC54) from 
CRAPome repository and one from our own HA control. To calculate SAINT scores (Choi et al., 
2012), spectral counts were analyzed using SAINT parameters “Lowmode = 0, MinFold = 0, 
Normalize=1”. The presented SAINT score was the average probability of SAINT results from all 
three biological replicates. Fold change (FC) is the ratio of the normalized spectral counts of a 
potential HectD1-interactor to the average of three highest normalized spectral counts of that 
protein across the negative controls. We chose the cutoff of SAINT score ≥0.5 and fold change 
(FC) ≥3 based on the established HectD1-interactors (RIOK2, (Varjosalo et al., 2013); ZRANB1, 
(Tran et al., 2013); SMC2, (Li et al., 2015)). ZNF622 was among the top hits of all 3 replicates 
(Supplemental Excel). Gene Ontology (GO) analysis of HectD1-interacting proteins was 
performed using PANTHER Classification System (http://pantherdb.org) (Mi et al., 2019). 
 
Polysome profiling 
20~30 million TF-1 cells with shLuc or shHECTD1 were pre-treated with 100 ug/mL 
cycloheximide (CHX) for 5min and washed with ice-cold CHX-containing PBS. After 
centrifugation, cell pellets were lysed in polysome lysis buffer (20mM Tris, pH7.5, 1.5mM MgCl2, 
140mM KCl, 1% Triton X-100, 100ug/mL CHX, 0.5mM DTT, protease inhibitor cocktail) for 
10min in ice with gentle rocking. The cell lysate was clarified by centrifugation at 17,000g for 
10min at 4°C. OD260 value was measured in Nanodrop. Linear sucrose gradient (7%-45%) was 
generated using a Gradient Maker (BioComp Instruments, Canada). 15-20 OD260 of total cell 
extract was loaded on the sucrose gradient, followed by ultracentrifugation at 35,000rpm for 3hrs 
20min at 4°C in SW40 rotor. Polysome profiling was analyzed with a BioComp fractionator. 
 
For detection of protein distribution, a total of 13 fractions (830uL/fraction) from polysome 
profiling were collected by a fraction collector (Cat# 4422151, FC-203B, Gilson). To extract 
proteins for Western Blot (WB) analysis, 150uL of each fraction was pelleted by methanol-
choloform-H2O precipitation with sequential addition of 600uL ice-cold methanol, 225uL 
chloroform and 450uL H2O. The reaction was thoroughly mixed by inversion and centrifuged at 
20,000g for 4min at 4°C. After carefully removing the aqueous layer, 1mL prechilled methanol 
was added and mixed by inversion, followed by centrifugation at 20,000g for 4min at 4°C. The 
supernatant was then decanted, and the protein pellet was dried at room temperature. 50uL 1*LDS 
loading solution was directly added to dissolve protein pellets by frequent pipetting up and down. 
Due to the extra abundance of proteins in cytoplasmic fractions 1-3, 2uL of fractions 1-3 along 
with 20uL of fractions 4-13 (different ribosomal fractions) were loaded onto an SDS-PAGE for 
WB analysis. 
 
Ribosomal subunit dissociation and re-association assay 
This assay was adapted from a previously published work (Burwick et al., 2012). For ribosomal 
subunit dissociation, 20~30 TF-1 cells were harvested without cycloheximide treatment and lysed 
with low Mg2+ buffer (20mM Tris, pH7.4, 140mM KCl, 0.25mM MgCl2, 0.5mM DTT, 1% Triton 
X-100, EDTA-free protease inhibitor cocktail (Roche)) for 10min on ice. After clarification by 
centrifugation at 17,000g for 5min at 4°C, the cell lysate was divided into two aliquots. One aliquot 
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was loaded on a 7-45% low Mg2+ sucrose gradient (20mM Tris, pH7.4, 140mM KCl, 0.25mM 
MgCl2, 0.5mM DTT, EDTA-free protease inhibitor cocktail (Roche)) and analyzed with a 
BioComp fractionator to detect total 40S and 60S. 
 
For ribosomal subunit re-association, 2.5M MgCl2 was added to the other aliquot for a final 
concentration of 10mM Mg2+ and incubated for 5min at 37°C. The resultant cell lysate was loaded 
on a 7-45% high Mg2+ sucrose gradient (20mM Tris, pH7.4, 140mM KCl, 10mM MgCl2, 0.5mM 
DTT, EDTA-free protease inhibitor cocktail (Roche)) and analyzed with a BioComp fractionator. 
 
Denatured His-ubiquitination assay  
293T cells were transfected with indicated HectD1 and ZNF622 constructs, as well as His-tagged 
Ub WT, K48R or K63R mutants. 2 days later, cells were harvested and washed with cold PBS 
twice, and then lysed with denatured Urea Lysis buffer (100mM Na2HPO4, 100mM NaH2PO4, 
10mM Tris, pH8.0, 0.2% Triton X-100, 5mM β-Mercaptoethanol, 10mM Imidazole, 8M urea), 
followed by immediate vortex and rocking at RT for 20min. After centrifuging for 10min at 
15,000g, supernatant was obtained and incubated with HisPur Ni-NTA resin (88221 Thermo 
Scientific) for 2 hrs at RT. Resin was then washed 3 times with wash buffer (100mM Na2HPO4, 
100mM NaH2PO4, 10mM Tris, pH6.3, 0.2% Triton X-100, 5mM β-Mercaptoethanol, 20mM 
Imidazole, 8M urea). Bound ubiquitinated proteins were eluted with SDS elution buffer (200mM 
Imidazole, 5% SDS, 150mM Tris, pH6.8, 30% glycerol, 720mM β-Mercaptoethanol) and 
subjected to western blot analysis. 
 
Cytokine signaling, protein half-life assay and Western blot (WB) 
For cytokine signaling, TF-1/MPL cells were stared in RPMI-1640 media plus 0.5% BSA for 2-
4hrs, and then stimulated with TPO for indicated time points and snap-frozen in dry ice. For mTOR 
signaling, we also stimulated starved cells with a graded concentration of calf serum. Cell pellets 
were lysed in LDS loading buffer and sonicated for homogenization. For measuring protein half-
life, cycloheximide (CHX) was employed to block de novo protein synthesis for different time 
points prior to cell harvest.  
 
Protein lysates were subjected to standard WB protocols. Briefly, samples were resolved by SDS-
PAGE, and transferred to NC membrane. For all primary phosphor-antibody blots, membranes 
were blocked with 5% BSA (BP1600-100, Fisher Bioreagents) in TBS-T, while other primary 
antibody blots were blocked with 5% non-fat milk (sc2325, Santa Cruz). Membranes were 
incubated with primary antibodies for 2hrs at room temperature or overnight in cold room. 
Following primary antibody blots, membranes were washed with TBS-T extensively, and then 
incubated with HRP-conjugated secondary antibody for 1hr at room temperature. After extensive 
washing, membranes were developed with ECL (#34095, Thermo Scientific). To compare 
immunoblots with a large number of samples that require multiple gels, samples were resolved in 
SDS-PAGE gels in parallel. Immunoblots were processed and developed side by side, then images 
were placed side-by-side for presentation.  
 
HSC cell growth and MTT proliferation assay 
100 LT-HSCs from Hectd1f/f or Hectd1f/f;Vav mice were sorted into round-bottom 96-well plate and 
cultured in SFEM (StemCell Technologies Inc.) supplemented with 10% FBS and various 
combinations or concentrations of cytokines as indicated in the main text. At different days, cell 
numbers were enumerated in the presence of trypan blue using a hemacytometer slide.  
 
TF-1/MPL cells with shLuc or shHECTD1 were cultured in an increasing dose of GM-CSF or 
TPO in a 96-well plate (10k cells/100uL per well) for 3 days. 3-(4,5-dimethylthiazole-2-yl)-2,5-
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diphenyl tetrazolium bromide (MTT; M6494, Invitrogen) was added to media at a final 
concentration of 0.5 mg/mL for 3-4 hrs at 37°C. Stopping buffer (15% SDS, 2.5% Acetic acid, 50% 
dimethylformamide) was then added to terminate the reaction. The absorbance was read by a 
spectrophotometer at 570 nm. 
 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Statistics for MTT, HSC cell growth and CFC assays were performed using unpaired two-tailed 
Student’s t test and error bars indicate mean± SD. Signal intensities of Western blot bands were 
quantified by Fiji software. Statistics was analyzed using unpaired two-tailed Student’s t test. All 
the relevant quantifications performed in primary mice or transplanted mice were analyzed by 
GraphPad Prism and error bars indicate mean± SEM. Paired t test was used for pairwise 
comparison of HSC/MPP numbers in Cyclophosphamide+2GCSF challenged mice. Details of “n” 
values describing the number of experiment repeats or mice are shown in the figure legends. 









Aleidi, S.M., Yang, A., Sharpe, L.J., Rao, G., Cochran, B.J., Rye, K.A., Kockx, M., Brown, A.J., 
and Gelissen, I.C. (2018). The E3 ubiquitin ligase, HECTD1, is involved in ABCA1-mediated 
cholesterol export from macrophages. Biochim Biophys Acta Mol Cell Biol Lipids 1863, 359-
368. 
Balcerek, J., Jiang, J., Li, Y., Jiang, Q., Holdreith, N., Singh, B., Chandra, V., Lv, K., Ren, J.G., 
Rozenova, K., et al. (2018). Lnk/Sh2b3 deficiency restores hematopoietic stem cell function and 
genome integrity in Fancd2 deficient Fanconi anemia. Nat Commun 9, 3915. 
Barilari, M., Bonfils, G., Treins, C., Koka, V., De Villeneuve, D., Fabrega, S., and Pende, M. 
(2017). ZRF1 is a novel S6 kinase substrate that drives the senescence programme. EMBO J 36, 
736-750. 
Bersenev, A., Wu, C., Balcerek, J., and Tong, W. (2008). Lnk controls mouse hematopoietic 
stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest 118, 
2832-2844. 
Boocock, G.R., Morrison, J.A., Popovic, M., Richards, N., Ellis, L., Durie, P.R., and Rommens, 
J.M. (2003). Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet 
33, 97-101. 
Burwick, N., Coats, S.A., Nakamura, T., and Shimamura, A. (2012). Impaired ribosomal subunit 
association in Shwachman-Diamond syndrome. Blood 120, 5143-5152. 
Chauvin, C., Koka, V., Nouschi, A., Mieulet, V., Hoareau-Aveilla, C., Dreazen, A., Cagnard, N., 
Carpentier, W., Kiss, T., Meyuhas, O., et al. (2014). Ribosomal protein S6 kinase activity 
controls the ribosome biogenesis transcriptional program. Oncogene 33, 474-483. 
Chen, M.J., Yokomizo, T., Zeigler, B.M., Dzierzak, E., and Speck, N.A. (2009). Runx1 is 
required for the endothelial to haematopoietic cell transition but not thereafter. Nature 457, 887-
891. 
Choi, H., Liu, G., Mellacheruvu, D., Tyers, M., Gingras, A.C., and Nesvizhskii, A.I. (2012). 
Analyzing protein-protein interactions from affinity purification-mass spectrometry data with 
SAINT. Curr Protoc Bioinformatics Chapter 8, Unit8 15. 
D'Alonzo, D., Emch, F.H., Shen, X., Bruder, E., De Geyter, C., and Zhang, H. (2019). Hectd1 is 
essential for embryogenesis in mice. Gene Expr Patterns 34, 119064. 
de la Cruz, J., Karbstein, K., and Woolford, J.L., Jr. (2015). Functions of ribosomal proteins in 
assembly of eukaryotic ribosomes in vivo. Annu Rev Biochem 84, 93-129. 
Dhanraj, S., Matveev, A., Li, H., Lauhasurayotin, S., Jardine, L., Cada, M., Zlateska, B., Tailor, 
C.S., Zhou, J., Mendoza-Londono, R., et al. (2017). Biallelic mutations in DNAJC21 cause 
Shwachman-Diamond syndrome. Blood 129, 1557-1562. 
Duhamel, S., Goyette, M.A., Thibault, M.P., Filion, D., Gaboury, L., and Cote, J.F. (2018). The 
E3 Ubiquitin Ligase HectD1 Suppresses EMT and Metastasis by Targeting the +TIP ACF7 for 
Degradation. Cell Rep 22, 1016-1030. 
Eng, J.K., McCormack, A.L., and Yates, J.R. (1994). An approach to correlate tandem mass 
spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass 
Spectrom 5, 976-989. 
Finch, A.J., Hilcenko, C., Basse, N., Drynan, L.F., Goyenechea, B., Menne, T.F., Gonzalez 
Fernandez, A., Simpson, P., D'Santos, C.S., Arends, M.J., et al. (2011). Uncoupling of GTP 
hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndrome. Genes 
Dev 25, 917-929. 
Greber, B.J., Boehringer, D., Montellese, C., and Ban, N. (2012). Cryo-EM structures of Arx1 




Greber, B.J., Gerhardy, S., Leitner, A., Leibundgut, M., Salem, M., Boehringer, D., Leulliot, N., 
Aebersold, R., Panse, V.G., and Ban, N. (2016). Insertion of the Biogenesis Factor Rei1 Probes 
the Ribosomal Tunnel during 60S Maturation. Cell 164, 91-102. 
Holcik, M., and Sonenberg, N. (2005). Translational control in stress and apoptosis. Nat Rev 
Mol Cell Biol 6, 318-327. 
Hu, Y., and Smyth, G.K. (2009). ELDA: extreme limiting dilution analysis for comparing 
depleted and enriched populations in stem cell and other assays. J Immunol Methods 347, 70-78. 
Jiang, J., Balcerek, J., Rozenova, K., Cheng, Y., Bersenev, A., Wu, C., Song, Y., and Tong, W. 
(2012). 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor 
cells. J Clin Invest 122, 2079-2091. 
Kargas, V., Castro-Hartmann, P., Escudero-Urquijo, N., Dent, K., Hilcenko, C., Sailer, C., 
Zisser, G., Marques-Carvalho, M.J., Pellegrino, S., Wawiorka, L., et al. (2019). Mechanism of 
completion of peptidyltransferase centre assembly in eukaryotes. Elife 8. 
Kisly, I., Remme, J., and Tamm, T. (2019). Ribosomal protein eL24, involved in two 
intersubunit bridges, stimulates translation initiation and elongation. Nucleic Acids Res 47, 406-
420. 
Klinge, S., and Woolford, J.L., Jr. (2019). Ribosome assembly coming into focus. Nat Rev Mol 
Cell Biol 20, 116-131. 
Li, W., Hu, Y., Oh, S., Ma, Q., Merkurjev, D., Song, X., Zhou, X., Liu, Z., Tanasa, B., He, X., et 
al. (2015). Condensin I and II Complexes License Full Estrogen Receptor alpha-Dependent 
Enhancer Activation. Mol Cell 59, 188-202. 
Liaud, N., Horlbeck, M.A., Gilbert, L.A., Gjoni, K., Weissman, J.S., and Cate, J.H.D. (2019). 
Cellular response to small molecules that selectively stall protein synthesis by the ribosome. 
PLoS Genet 15, e1008057. 
Liu, J., Xu, Y., Stoleru, D., and Salic, A. (2012). Imaging protein synthesis in cells and tissues 
with an alkyne analog of puromycin. Proc Natl Acad Sci U S A 109, 413-418. 
Lo, K.Y., Li, Z., Bussiere, C., Bresson, S., Marcotte, E.M., and Johnson, A.W. (2010). Defining 
the pathway of cytoplasmic maturation of the 60S ribosomal subunit. Mol Cell 39, 196-208. 
Lv, K., Jiang, J., Donaghy, R., Riling, C.R., Cheng, Y., Chandra, V., Rozenova, K., An, W., 
Mohapatra, B.C., Goetz, B.T., et al. (2017). CBL family E3 ubiquitin ligases control JAK2 
ubiquitination and stability in hematopoietic stem cells and myeloid malignancies. Genes Dev 
31, 1007-1023. 
Ma, C., Wu, S., Li, N., Chen, Y., Yan, K., Li, Z., Zheng, L., Lei, J., Woolford, J.L., Jr., and Gao, 
N. (2017). Structural snapshot of cytoplasmic pre-60S ribosomal particles bound by Nmd3, 
Lsg1, Tif6 and Reh1. Nat Struct Mol Biol 24, 214-220. 
Mellacheruvu, D., Wright, Z., Couzens, A.L., Lambert, J.P., St-Denis, N.A., Li, T., Miteva, 
Y.V., Hauri, S., Sardiu, M.E., Low, T.Y., et al. (2013). The CRAPome: a contaminant repository 
for affinity purification-mass spectrometry data. Nat Methods 10, 730-736. 
Menne, T.F., Goyenechea, B., Sanchez-Puig, N., Wong, C.C., Tonkin, L.M., Ancliff, P.J., Brost, 
R.L., Costanzo, M., Boone, C., and Warren, A.J. (2007). The Shwachman-Bodian-Diamond 
syndrome protein mediates translational activation of ribosomes in yeast. Nat Genet 39, 486-495. 
Meyer, A.E., Hoover, L.A., and Craig, E.A. (2010). The cytosolic J-protein, Jjj1, and Rei1 
function in the removal of the pre-60 S subunit factor Arx1. J Biol Chem 285, 961-968. 
Mi, H., Muruganujan, A., Ebert, D., Huang, X., and Thomas, P.D. (2019). PANTHER version 
14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. 
Nucleic Acids Res 47, D419-D426. 
Modlich, U., Schambach, A., Li, Z., and Schiedlmeier, B. (2009). Murine hematopoietic stem 
cell transduction using retroviral vectors. Methods Mol Biol 506, 23-31. 
 
 41 
Morrison, S.J., Wright, D.E., and Weissman, I.L. (1997). Cyclophosphamide/granulocyte 
colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. 
Proc Natl Acad Sci U S A 94, 1908-1913. 
Oguro, H., Ding, L., and Morrison, S.J. (2013). SLAM family markers resolve functionally 
distinct subpopulations of hematopoietic stem cells and multipotent progenitors. Cell Stem Cell 
13, 102-116. 
Peng, J., and Gygi, S.P. (2001). Proteomics: the move to mixtures. J Mass Spectrom 36, 1083-
1091. 
Pietras, E.M., Reynaud, D., Kang, Y.A., Carlin, D., Calero-Nieto, F.J., Leavitt, A.D., Stuart, 
J.M., Gottgens, B., and Passegue, E. (2015). Functionally Distinct Subsets of Lineage-Biased 
Multipotent Progenitors Control Blood Production in Normal and Regenerative Conditions. Cell 
Stem Cell 17, 35-46. 
Rodriguez, C.I., Buchholz, F., Galloway, J., Sequerra, R., Kasper, J., Ayala, R., Stewart, A.F., 
and Dymecki, S.M. (2000). High-efficiency deleter mice show that FLPe is an alternative to Cre-
loxP. Nat Genet 25, 139-140. 
Rozenova, K., Jiang, J., Donaghy, R., Aressy, B., Greenberg, R.A., and Tong, W. (2015). 
MERIT40 deficiency expands hematopoietic stem cell pools by regulating thrombopoietin 
receptor signaling. Blood 125, 1730-1738. 
Ruggero, D., and Shimamura, A. (2014). Marrow failure: a window into ribosome biology. 
Blood 124, 2784-2792. 
Sarkar, A.A., Nuwayhid, S.J., Maynard, T., Ghandchi, F., Hill, J.T., Lamantia, A.S., and Zohn, 
I.E. (2014). Hectd1 is required for development of the junctional zone of the placenta. Dev Biol 
392, 368-380. 
Sarkar, A.A., and Zohn, I.E. (2012). Hectd1 regulates intracellular localization and secretion of 
Hsp90 to control cellular behavior of the cranial mesenchyme. J Cell Biol 196, 789-800. 
Shembade, N., and Harhaj, E.W. (2015). Elucidating dynamic protein-protein interactions and 
ubiquitination in NF-kappaB signaling pathways. Methods Mol Biol 1280, 283-295. 
Shevchenko, A., Wilm, M., Vorm, O., and Mann, M. (1996). Mass spectrometric sequencing of 
proteins silver-stained polyacrylamide gels. Anal Chem 68, 850-858. 
Signer, R.A., Magee, J.A., Salic, A., and Morrison, S.J. (2014). Haematopoietic stem cells 
require a highly regulated protein synthesis rate. Nature 509, 49-54. 
Signer, R.A., Qi, L., Zhao, Z., Thompson, D., Sigova, A.A., Fan, Z.P., DeMartino, G.N., Young, 
R.A., Sonenberg, N., and Morrison, S.J. (2016). The rate of protein synthesis in hematopoietic 
stem cells is limited partly by 4E-BPs. Genes Dev 30, 1698-1703. 
Stadtfeld, M., and Graf, T. (2005). Assessing the role of hematopoietic plasticity for endothelial 
and hepatocyte development by non-invasive lineage tracing. Development 132, 203-213. 
Sugrue, K.F., Sarkar, A.A., Leatherbury, L., and Zohn, I.E. (2019). The ubiquitin ligase 
HECTD1 promotes retinoic acid signaling required for development of the aortic arch. Dis 
Model Mech 12. 
Sulima, S.O., Hofman, I.J.F., De Keersmaecker, K., and Dinman, J.D. (2017). How Ribosomes 
Translate Cancer. Cancer Discov 7, 1069-1087. 
Tan, S., Kermasson, L., Hoslin, A., Jaako, P., Faille, A., Acevedo-Arozena, A., Lengline, E., 
Ranta, D., Poiree, M., Fenneteau, O., et al. (2019). EFL1 mutations impair eIF6 release to cause 
Shwachman-Diamond syndrome. Blood 134, 277-290. 
Tran, H., Bustos, D., Yeh, R., Rubinfeld, B., Lam, C., Shriver, S., Zilberleyb, I., Lee, M.W., Phu, 
L., Sarkar, A.A., et al. (2013). HectD1 E3 ligase modifies adenomatous polyposis coli (APC) 
with polyubiquitin to promote the APC-axin interaction. J Biol Chem 288, 3753-3767. 
Tummala, H., Walne, A.J., Williams, M., Bockett, N., Collopy, L., Cardoso, S., Ellison, A., 
Wynn, R., Leblanc, T., Fitzgibbon, J., et al. (2016). DNAJC21 Mutations Link a Cancer-Prone 
 
 42 
Bone Marrow Failure Syndrome to Corruption in 60S Ribosome Subunit Maturation. Am J Hum 
Genet 99, 115-124. 
Warren, A.J. (2018). Molecular basis of the human ribosomopathy Shwachman-Diamond 
syndrome. Advances in biological regulation 67, 109-127. 
Weis, F., Giudice, E., Churcher, M., Jin, L., Hilcenko, C., Wong, C.C., Traynor, D., Kay, R.R., 
and Warren, A.J. (2015). Mechanism of eIF6 release from the nascent 60S ribosomal subunit. 
Nat Struct Mol Biol 22, 914-919. 
Wilson, A., Laurenti, E., Oser, G., van der Wath, R.C., Blanco-Bose, W., Jaworski, M., Offner, 
S., Dunant, C.F., Eshkind, L., Bockamp, E., et al. (2008). Hematopoietic stem cells reversibly 
switch from dormancy to self-renewal during homeostasis and repair. Cell 135, 1118-1129. 
Woloszynek, J.R., Rothbaum, R.J., Rawls, A.S., Minx, P.J., Wilson, R.K., Mason, P.J., Bessler, 
M., and Link, D.C. (2004). Mutations of the SBDS gene are present in most patients with 
Shwachman-Diamond syndrome. Blood 104, 3588-3590. 
Wong, C.C., Traynor, D., Basse, N., Kay, R.R., and Warren, A.J. (2011). Defective ribosome 
assembly in Shwachman-Diamond syndrome. Blood 118, 4305-4312. 
Zohn, I.E., Anderson, K.V., and Niswander, L. (2007). The Hectd1 ubiquitin ligase is required 






CRU 1 in 13,200 1 in 55,300
Range 
±1SE
1 in 23,700 to 
1 in 7,460





















































































































































































































4W            8W          12W          16W
*** *** ***



































4W 8W 12W 16W
***
*** *** ***

































































4W 8W 12W 16W
***
*** ** **

















































































500 HSCs   
(LSK CD150+CD48-)





























































































































































































































































































- - +  +  +  +   +




































































































































































































(Cy+2 GCSF)E F G H




































































































































































































































































   HSC    MPP
Figure




























































































































































































































































































































1   2  3  4 5   6 7 8 9 10 11 12 13













































































































































































































































+   - -
- +   -
- - +
+   - -
- +   -
- - +
+   - -










































































Figure S1. Generation of hematopoietic-specific Hectd1 conditional knockout mice. Related to Figure 1. 
(A) Strategy of generating Vav-cre mediated conditional Hectd1 knockout (Hectd1 f/f;Vav) mice. Exon3 was flanked by floxP 
sites. Deletion of exon 3 results in an early stop codon in exon4, producing a 50 aa (amino acid) truncated protein.  
(B) Genotyping of individual bone marrow-derived hematopoietic colonies from Hectd1 f/f and Hectd1 f/f;Vav mice to evaluate 
Hectd1 deletion efficiency.   
(C) RT-qPCR analysis to evaluate the deletion efficiency of Hectd1 at the mRNA level. Hectd1 contains 43 exons. qPCR 
primer pairs targeting to exon 3 are designed and used for qPCR analysis. BM cells from two mice of each genotype were 
tested.  
(D) As negative controls, qPCR primer pairs targeted to Hectd1 exon 6, 22, 38 were designed and used to confirm the 
specificity of Hectd1 excision in mice.  
(E) Western blot analysis of BM cells to confirm Hectd1 knockout efficiency at the protein level. Data are represented by 









Figure S1, related to Figure 1.
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Figure S2. Hematopoietic-specific Hectd1 knockout mice show relatively normal steady-state hematopoiesis. Related 
to Figure 1. 
(A) Complete blood count (CBC) analysis of peripheral blood (PB) from Hectd1 f/f (n=13) and Hectd1 f/f;Vav (n=13) mice. 
WBC, whole blood count; NE, neutrophils; LY, lymphocytes; MO, monocytes; PLT, platelets; RBC, red blood cells; HB, 
hemoglobin; HCT, hematocrit.  
(B) Lineage cell percentages in the PB of Hectd1f/f (n=8) and Hectd1 f/f;Vav (n=11) mice were analyzed by flow cytometry.   
(C) Total BM cellularity of Hectd1f/f (n=5) and Hectd1 f/f;Vav (n=6) mice.  
(D) Spleen weight of Hectd1f/f (n=5) and Hectd1 f/f;Vav (n=5) mice.  
(E, F) Flow cytometry analysis of the frequency of various HSPC subpopulations in BM (E) and spleen (F) of Hectd1f/f 
(n=5) and Hectd1 f/f;Vav (n=6) mice. Long-term hematopoietic stem cell (LT-HSC) is defined as CD150+CD48-Flk2-LSK 
cells. Short-term HSC (ST-HSC): CD150-CD48-Flk2-LSK. MPP2: CD150+CD48+Flk2-LSK. MPP3: CD150-CD48+Flk2-
LSK. MPP4: CD150- Flk2+LSK.  
(G-H) Cell numbers of HSPC subpopulations in BM (G) and spleen (H) of Hectd1f/f (n=5) and Hectd1 f/f;Vav (n=5) mice.  
(I, J) Frequency (I) and cell number (J) of different hematopoietic progenitors in BM of Hectd1f/f (n=5) and Hectd1 f/f;Vav 
(n=6) mice as determined by flow cytometry are shown.  
(K) Colony-forming units (CFU)-E (left) and CFU-G/M (right) of the BM are shown.  
(L, M), Frequency (L) and cell number (M) of different hematopoietic progenitors in the spleen of Hectd1f/f (n=5) and 
Hectd1 f/f;Vav (n=6) mice are shown.  
(N) CFU-E (left) and CFU-G/M (right) analysis of the spleen are shown.  
(O-P) Cell cycle analysis of HSCs (O) and MPPs (P) in primary Hectd1f/f (n=5) and Hectd1 f/f;Vav (n=5) mice as determined 
by Ki67 and DAPI. 
(Q) Cell apoptosis analysis of LSKs, HSCs and MPPs in primary Hectd1f/f (n=4) and Hectd1 f/f;Vav (n=3) mice by Annexin 
V staining.  
All the experiments above were performed in 8-10 weeks old young mice. Each symbol represents an individual mouse; 
bars indicate mean values; error bars indicate SE. *: p<0.05; **: p<0.01; ***: p<0.001; ns: not significant, as determined 
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Figure S3A-G: related to figure 1; H-K: related to figure 2. 












































































































































































MPP/HPC BMT: T CellMPP/HPC BMT: B CellMPP/HPC BMT: Myeloid
Figure S3. Loss of Hectd1 does not impair hematopoietic differentiation, bone marrow niche or MPP reconstitution 
in transplanted mice. Panels S3A-S3K are related to figure 1 and panels S3L-S3M are related to figure 2. 
(A-D) Loss of Hectd1 does not impair hematopoietic differentiation in transplanted mice. Examination of donor HSC 
differentiation in competitive total BM transplanted mice. 1*106 unfractionated BM cells from Hectd1f/f and Hectd1f/f;Vav 
mice were injected with the same number of competitor BM cells into lethally irradiated recipient mice. Donor chimerisms 
in different lineages of the PB were shown. (A) Granulocytes, (B) monocytes, (C) B cells and (D) T cells.  Hectd1f/f (n=11) 
and Hectd1f/f;Vav (n=11). 
(E-G) Hectd1 deficiency leads to a decreased donor reconstitution in limiting dilution BMT. Donor cell percentage in 
recipients’ PB injected with 100k (E), 30k (F), 10k (G) donor BM cells mixed with 300k competitor BM cells were examined 
every 4 weeks post-BMT.  100k: Hectd1f/f (n=5) and Hectd1f/f;Vav (n=6); 30k: Hectd1f/f (n=10) and Hectd1f/f;Vav (n=13); 10k: 
Hectd1f/f (n=9) and Hectd1f/f;Vav (n=7). 
(H-K) Hectd1 deficiency does not affect bone marrow niche as shown in reciprocal BMT.  
(H) Experimental scheme of reciprocal BMT. 1×106 total BM cells from SJL mice (CD45.1) were transplanted into lethally-
irradiated Hectd1f/f (n=8) and Hectd1 f/f;Vav (n=7)  littermates (CD45.2).  
(I) Donor chimerism was analyzed by flow cytometry every 4 weeks post-BMT.  
(J) Donor-derived cells in each lineage 16 weeks post-BMT are shown.  
(K) Donor percentages in different HSPC subpopulations in the BM of Hectd1f/f and Hectd1 f/f;Vav recipient mice are shown.  
(L-M) HectD1 is required for HSC but not MPP/HPC reconstitution ability.  
(L) Percentages of donor HSC-derived myeloid cells (Gr1/Mac1+), B cells (B220+) and T cells (CD4+CD8+) are shown.  
(M) Percentages of donor MPP/HPC-derived myeloid cells (Gr1/Mac1+), B cells (B220+) and T cells (CD4+CD8+) are 
shown.  
In all relevant panels, each symbol represents an individual mouse; bars indicate mean frequencies; error bars indicate SE. 
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Figure S4. Hectd1 deficiency decreases RPS6 phosphorylation independent of the mTOR pathway. Related to figure 
3. 
(A-B) Hectd1 deficiency decreases RPS6 phosphorylation in 2 day-cultured LSK cells.  
(A) A diagram showing different signaling pathways that we examined in LSKs and TF-1 cells.  
(B) Two-day cultured LSKs from Hectd1f/f and Hectd1 f/f;Vav  mice were used to examine various  signaling molecules in the 
mTOR pathway, peIF2a, and JAK/STAT, PI3K-AKT, MAPK pathways by WB.  
(C-E) HECTD1 depletion in TF-1 cells recapitulates the signaling properties observed in Hectd1-deficient LSK cells. 
(C-D) Signal kinetics (C) and sensitivity to cytokines (D) of JAK-STAT, PI3K-AKT, RAS-ERK and mTOR pathways were 
compared in shLuc and shHECTD1 TF-1/MPL cells stimulated with hTPO.  
(E) Activation of the mTOR pathway was compared in shLuc vs shHECTD1 cells upon stimulation of a graded 
concentration of fetal calf serum (FCS). Phospho-RPS6 (pRPS6) are highlighted in red. 
(F-J) HectD1 does not affect RPS6 ubiquitination, S6K1-RPS6 interaction or the transcription of RiBi genes. 
(F) 293T cells were transfected with constructs expressing HA control or HA-tagged HectD1 WT or HectdD1 E3-dead 
mutant C2579G. 48hrs later, cells were treated with or without proteasome inhibitor MG132 for 2hr, followed by His-Ub 
pull down under denatured conditions.  
(G) 293T cells transfected with HA control or HA-tagged HectD1 WT or mutant C2579G were either untreated or deprived 
of serum. Activation of S6K1 and RPS6 by serum is shown in the WB (Pre-IP). S6K1-RPS6 interaction was assessed by 
S6K1 immunoprecipitation (IP) followed by WB with anti-RPS6 antibodies.  
(H) HectD1 depletion does not affect S6K1-RPS6 interaction as determined by IP/WB in TF-1 cells. 
(I) Total RNA was extracted and compared in HSCs and MPPs of Hectd1f/f and Hectd1 f/f;Vav  mice.  
(J) qRT-PCR analysis of the gene expression of RiBi proteins and ribosome proteins in HSCs of Hectd1f/f and Hectd1 f/f;Vav  
















































































































DNA replication factor C complex (GO:0005663) 2/5 > 100 3.18E-04 1.49E-02
3M complex (GO:1990393) 2/5 > 100 3.18E-04 1.45E-02
paraspeckles (GO:0042382) 2/6 84.32 4.22E-04 1.77E-02
proteasome regulatory particle, lid subcomplex 
(GO:0008541) 2/8 63.24 6.75E-04 2.47E-02
chaperonin-containing T-complex (GO:0005832) 2/11 45.99 1.16E-03 3.77E-02
eukaryotic translation initiation factor 4F complex 
(GO:0016281) 2/13 38.92 1.56E-03 4.75E-02
exocyst (GO:0000145) 3/20 37.94 9.85E-05 6.01E-03
proteasome regulatory particle (GO:0005838) 3/22 34.5 1.27E-04 7.53E-03
proteasome accessory complex (GO:0022624) 3/25 30.36 1.80E-04 9.77E-03
Flemming body (GO:0090543) 3/31 24.48 3.23E-04 1.44E-02
cytosolic  small ribosomal subunit (GO:0022627) 4/47 21.53 4.85E-05 3.25E-03
cytoplasmic stress granule (GO:0010494) 5/68 18.6 1.02E-05 8.56E-04
mitochondrial nucleoid (GO:0042645) 3/44 17.25 8.42E-04 2.97E-02
nucleoid (GO:0009295) 3/44 17.25 8.42E-04 2.92E-02
polysome (GO:0005844) 5/75 16.86 1.60E-05 1.24E-03
proteasome complex (GO:0000502) 4/66 15.33 1.68E-04 9.67E-03
endopeptidase complex (GO:1905369) 4/67 15.1 1.78E-04 9.93E-03
ficolin-1-rich granule (GO:0101002) 7/124 14.28 8.54E-07 2.15E-04
ficolin-1-rich granule lumen (GO:1904813) 7/4/124 14.28 8.54E-07 1.91E-04
small ribosomal subunit (GO:0015935) 4/79 12.81 3.24E-04 1.42E-02
cytosolic ribosome (GO:0022626) 5/111 11.39 9.54E-05 6.00E-03
growth cone (GO:0030426) 8/187 10.82 1.01E-06 1.85E-04
peptidase complex (GO:1905368) 4/94 10.76 6.09E-04 2.41E-02
site of polarized growth (GO:0030427) 8/195 10.38 1.37E-06 2.30E-04
midbody (GO:0030496) 7/182 9.73 9.74E-06 8.52E-04
nuclear matrix (GO:0016363) 4/108 9.37 1.00E-03 3.37E-02
ribosome (GO:0005840) 8/247 8.19 7.41E-06 6.78E-04
cytoplasmic ribonucleoprotein granule 
(GO:0036464) 7/224 7.91 3.55E-05 2.55E-03
ribonucleoprotein granule (GO:0035770) 7/235 7.54 4.77E-05 3.31E-03
secretory granule lumen (GO:0034774) 9/320 7.11 5.88E-06 7.39E-04
cytoplasmic vesicle lumen (GO:0060205) 9/324 7.03 6.48E-06 6.52E-04
vesicle lumen (GO:0031983) 9/326 6.98 6.80E-06 6.52E-04
distal axon (GO:0150034) 8/307 6.59 3.39E-05 2.53E-03
ribonucleoprotein complex (GO:1990904) 18/709 6.42 3.54E-10 1.78E-07
ribosomal subunit (GO:0044391) 5/197 6.42 1.22E-03 3.83E-02




























































































































































Figure S5. Panels S5A-S5F are related to figure3. Panels S5G-S5I, related to figure 4. 
(A) Gene Ontology (GO) cellular component analysis of HectD1 interactors identified in three biological replicates of HA-
HectD1 immunoprecipitation/mass spectrometry (IP/MS). GO categories with fold enrichment>5 and FDR cutoff of 5% 
are shown. 
(B-E) Mapping the interacting domains/regions of HectD1 and ZNF622 by IP/WB. 
(B) Schematic demonstration of HectD1 WT, E3-dead mutant (C2579G) and deletion mutants (Fragment1-5). Positive 
interaction is labeled with “+”; no interaction “-”.  
(C) HA-IP/WB in293T cells transfected with HA-tagged HectD1 WT or indicated mutants. Endogenous ZNF622 was 
immunoblotted. The full-length HectD1 band was marked by asterisk. Fragment 2 (F2) encompassing amino acid 396-613 
was lowly expressed and marked by a solid arrow. 
(D) Schematic demonstration of full-length ZNF622 and its deletion mutants. Positive interaction is labeled with “+”; no 
interaction “-”. 
(D) Flag-IP/WB in293T cells transfected with Flag-tagged ZNF622 FL or indicated truncates/mutants. Endogenous HectD1 
was immunoblotted. 
(F) qRT-PCR analysis of the mRNA level of ZNF622 in TF-1 cells with shLuc or shHECTD1#1 and #2. n=3 in each group. 
Data are represented by mean± SD. ns, not significant; ∗∗∗: p < 0.001, as determined by unpaired two-tailed Student’s t-
tests. 
(G-I) Both protein synthesis rate and cell apoptosis are not changed in primary Hectd1 f/f;Vav  mice.  
(A) Representative histogram of OP-Puro intensity in unfractionated BM cells and different subpopulations of stem and 
progenitor cells of a control mouse. 
(B) Quantification of relative protein synthesis rate in unfractionated BM cells and different subpopulations of stem and 
progenitor cells of Hectd1f/f (n=3) and Hectd1 f/f;Vav  (n=3) mice.  
(C) Cell apoptosis analysis of LSKs, HSCs and MPPs in 5-FU challenged Hectd1f/f (n=7) and Hectd1 f/f;Vav (n=6) mice by 
AnnexinV staining. Each symbol represents an individual mouse; bars indicate mean values; error bars indicate SE. ns: not 




Figure S6. HECTD1 depletion reduces phospho-RPS6, but not NMD3 or select RPLs in ribosome fractions. Panels 
S6A-S6F are related to figure 5; S6G, related to figure 6. 
(A-F) Quantification of the relative distribution of indicated proteins in three independent polysome profiling assays of 
shLuc and shHECTD1 TF-1 cells. Data are represented by mean± SE. ∗: p < 0.05; ns, not significant, as determined by 
unpaired two-tailed Student’s t-tests. 
(G) Knockdown of ZNF622 does not change the phosphorylation of eIF2a or mTOR activation. WB of indicated 
proteins in TF-1 cells with single or double knockdown of HECTD1 and ZNF622.  
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